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Abstract
For many years it has been recognised that a deprivation gap exists in breast cancer. 
While incidence is highest in affluent women, deprived women seem to do worse.
The reasons for this are not clear. Differences in tumour pathology or hormone 
receptor status may be responsible. Geographical differences exist in breast cancer 
survival and treatment by a specialist breast surgeon also seems to improve 
prognosis. However, many of these studies were done before the introduction of 
breast screening, which has undoubtedly changed the way in which breast cancer is 
diagnosed and treated. This thesis analyses the pathological and treatment data on a 
group of women who were diagnosed in Glasgow between 1996 and 2001, after 
breast screening as well as multidisciplinary teams had been established. The 
presence of a deprivation gap had previously been described in Glasgow. The aim of 
this thesis is to identify if there remains a survival gap between affluent and deprived 
women and to what extent treatment and pathology are responsible.
All women treated for primary operable invasive breast cancer in Glasgow between 
1995 and 1998 were analysed. In total, 1717 women were treated. Median follow 
up was just over 6 years. Overall 5 year survival was 80.4%. There was a trend for 
worse survival in the most deprived group (83.9% vs. 77.8% in the most affluent 
group) but this was not significant. Interestingly, deprived women had larger, node 
positive tumours and were more likely to be symptomatic but this did not affect 
survival. On multivariate analysis age, Nottingham prognostic index (NPI) and 
oestrogen receptor (ER) status were independent predictors of survival. These 
results suggest that the deprivation gap may no longer exist in Glasgow. While, 
follow up may not be long enough to identify a deprivation gap, the introduction of 
standardised treatment by multidisciplinary teams may have had an impact on 
narrowing the deprivation gap.
Surgical treatment for breast cancer can be by mastectomy or conservation surgery. 
The differences in survival suggest that perhaps surgeons themselves are treating 
affluent and deprived women differently. Women diagnosed between 1996 and 2001 
were analysed to see if surgical treatment varied between affluent and deprived 
women. 3419 women were eligible for conservation surgery by their tumour size.
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46.4 % underwent conservation surgery, the remainder had a mastectomy. Deprived 
women were significantly more likely to have a mastectomy (p<0.001). However, 
they had larger tumouis that were more likely to be symptomatic. On multivariate 
analysis, deprivation was related to likelihood of having a mastectomy. Deprived 
women were therefore treated appropriately and it was tumour size that deteimined 
surgery not biased treatment. There was, however, significant variation in 
mastectomy rate between hospitals suggesting that there is a lack of consensus on the 
best surgical management of primary operative breast cancer.
It has previously been shown that affluent women not only have a higher incidence 
of breast cancer but they are also more likely to have ER positive disease. ER 
positive breast cancer is more likely to respond to hormonal therapy and is less likely 
to recur, resulting in a better prognosis. It is also associated with nulliparity, late age 
at first birth, late menopause and HRT use. All of these reproductive factors have 
increased in the last 20 to 30 years but more so for affluent women. Two cohorts of 
patients were compared. The first were diagnosed 1980-1988 and had ER status 
determined by ligand binding assay, the second, diagnosed between 1996 and 2001, 
had ER determined by immunohistochemistry. The proportion of ER positive 
tumours rose from 50.1% in the early cohort to 79.3% in the late cohort. This 
increase was independent of age, deprivation or hospital of diagnosis (p<0.001). The 
proportion of ER positive breast cancers increased for all deprivation categories but 
there was no significant difference between the most and least deprived. Some of 
this rise is due to changes in the methodology of determining ER status; however, 
this does not explain all of the difference. Increases in the prevalence of the 
aetiological factors for ER positive breast cancer are, in some part, responsible.
Differences in the host response to the tumour may be responsible for survival 
differences. The systemic inflammatory response, as measured by C-reactive protein 
(CRP) to cancer predict prognosis in a variety of solid tumours. In addition, 
deprived people appear to have a raised “background” level of inflammation which 
may contribute to survival differences between rich and poor. CRP and IL-6, its 
inflammatory cytokine, were determined in a group of 194 patients both pre and post 
operatively. All patients were followed up for a median of 52 months. CRP was not 
related to deprivation. There was no difference in survival between deprivation
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categories. However, pre-operative CRP (p=0.03) but not post operative CRP 
independently predicted survival independent of age, deprivation, NPI, ER status and 
HER2 status. Combining pre and post operative CRP as a score gave a powerful 
predictor of survival (p^O.OOl). This suggests that patients with a raised background 
inflammatory response combined with the response to the tumour itself do especially 
badly.
There no longer appears to be a deprivation gap in survival for women with breast 
cancer. Differences in surgical treatment do, however, exist but this appears to be 
due to bigger tumours in deprived women. Hormonal, aetiological factors for ER 
positive breast cancer have increased overall for all women but this does not seem to 
contribute to socioeconomic differences in tumour pathology. The systemic 
inflammatory response may play a role in predicting survival from breast cancer but 
it does not appear to differ between social classes. Improvements in diagnosis and 
delivery of treatment must therefore play the largest role in narrowing the 
deprivation gap.
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Introduction
It is well known that breast cancer is the most common female malignancy and 1 in 9 
women in the UK will be diagnosed with breast cancer at some point in their lives. 
Extensive media coverage adds to public awareness of the disease. However, what is 
not so well known are the inequalities that exist in the disease. While affluent 
women are more likely to develop breast cancer it is socio-economically deprived 
women that are more likely to have a worse outcome. Many reasons for this have 
been suggested but they have never been fully elucidated. Much of the work that 
was done to examine reasons for these differences was done on populations of 
women in the pre-breast screening era. The introduction of breast screening has 
changed not only the way that breast cancer is diagnosed but it has also changed the 
pattern of the disease. This makes it time to revisit whether the deprivation gap still 
exists and to what extent pathological and treatment factors influence it.
Glasgow is one of the most socio-economically deprived urban areas in the UK. A 
rapid increase in industrialization followed by a rapid decline in industry has left 
Glasgow with high levels of socio-economic deprivation which makes it ideal for 
studying the effects of deprivation on cancer incidence and survival.
Like the rest of the world the incidence of breast cancer in Greater Glasgow is high 
and on the rise. Between 1990-1999 incidence was 108.5/1000, 000 (data from ISD 
Scotland) and overall incidence level has risen by around 25 % since 1980 (figl). 
Part of the reason for the rise in breast cancer incidence can be attributed to the 
introduction of breast screening in 1990. From the graph below a sharp increase is 
seen between 1990 and 1993 when the prevalent round of screening was completed. 
However, the incidence has continued to rise after this, so breast screening does not 
explain this trend.
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Fig 1: Trends in incidence: Age-standardised incidence rates per 100 000 person- 
years at risk (European standard population) for the period 1980-2003
Although the incidence of breast cancer is high, and continuing to rise, breast cancer 
survival is good at around 80% 5-year survival (1996 -  1998 data from Scottish 
Cancer Intelligence Unit). Mortality has improved significantly over the past 20-30 
years. The introduction of breast screening has contributed to this but undoubtedly 
improvements in the diagnosis and treatment of breast cancer have also made their 
contribution. Despite these general trends in breast cancer incidence and mortality, 
persistent differences exist in outcome between countries and within the same 
country.
1. Breast cancer incidence and mortality worldwide
1.1 Worldwide trends in Incidence.
Broadly speaking, breast cancer is a disease of the Western world. World-wide, it has 
the largest incidence in the most developed countries (Data from CAN 
web-page address: http://www-dep.iarc.fr/), with the USA and the Netherlands 
having the highest incidence. The lowest incidence occurs in developing countries, 
with Mozambique and Haiti having the lowest incidence (Data from 
CP^CERMondial, web-page address: http://www-dep.iarc.fr/). The variation in 
incidence between the most and least affluent countries is at least 10-fold. Studies of 
migrants to affluent countries have shown that the reasons for this wide variation in 
incidence are likely to be environmental rather than genetic. Comparisons of Asian
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women (an area of low incidence) who have migrated to the USA have shown that 
their offspring have a greater risk of breast cancer (1). Part of this reason may be due 
to the effect of mammographie screening. In affluent and highly resourced countries 
not only does the presence of screening increase the number of cancers detected it 
also results in better registration of breast cancer diagnoses. However, it appears that 
environmental factors inherent in the “Western lifestyle” are the main contributing 
factors.
The introduction of breast screening in the USA and Europe resulted in an increase 
in incidence as the prevalent round was completed (fig. 2). However, even before 
the introduction of screening incidence was increasing. In fact, while increases were 
being seen in the countries that had introduced screening there were similar marked 
rises being noted in countries that did not yet have a screening programme. Not only 
that, but increases were noted across all age groups, not just the screening age group 
(2). More recently, there does appear to have been a plateau in incidence although 
the level of incidence is higher than before the introduction of screening(2). While, 
improvements in cancer registration may have contributed to this phenomenon, 
breast screening does not explain why there should have been an increase in the non­
screened populations. Changes in the incidence of risk factors for breast cancer may 
therefore play a role.
Natasha C Henley, 2006
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Age-adjusted breast cancer incidence worldwide 
1973-77 to 1993-97
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Fig 2: Age-adjusted breast cancer incidence rates for US black and white women 
generated from nine SEER registries representing 9.5% of the population. Incidence 
data for all other countries abstracted from lARC Cancer Incidence in Five 
Continents (1973-77 to 1993-97) (3)
In Asia, where there is a relatively low incidence of breast cancer, there has been a 
rapid rise in incidence, which is more marked than in other regions of the world (fig. 
2). The majority of countries do not have a breast screening programme (with the 
exception of Japan) so this increase in incidence must be due to changing patterns of 
risk factors and environmental exposure (3). In developing countries there also 
appears to be an increase in incidence. There is a relative scarcity of high quality 
cancer registry data, however, what data there is, confirms that rising incidence of 
breast cancer is not peculiar to the Western world. In addition, it appears that the 
rate at which incidence is climbing is faster in developing countries, with the fastest 
rate of increase in the urban dwellers of those countries (2).
Thus development and the adaptation of the Western lifestyle seem to be more 
important than any genetic susceptibility. The risk factors which increase exposure
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to endogenous oestrogen that are associated with breast cancer (early age at 
menarche, nulliparity, late age at first birth, low parity and late menopause) are more 
prevalent in the Western world and are also associated with improved socio­
economic status (4). The use of hormone replacement therapy may also have a role 
to play as could obesity and reduced physical activity.
Interestingly, within countries incidence differs by socio-economic status. In all 
countries, regardless of whether they are developed or developing, affluent women 
have a greater incidence of breast cancer. Studies from Finland (5), the 
Netherlands(6), Denmark (7), the USA as well as in the UK (8;9) have all 
consistently shown that affluent women are more likely develop breast cancer. This 
adds weight to the argument that there is an environmental rather than a genetic 
reason for why women tend to develop breast cancer and, whatever this 
environmental influence is, it is likely to be associated with affluence.
Although it appears that increased breast cancer incidence is associated with the 
affluence and adaptation of the Western lifestyle, there does appear to be differences 
in the aetiology of breast cancer between different countries. If the patterns of 
incidence are further examined by comparing similar age groups of Japanese and 
American women, they are different (fig. 3). In the USA there is a sharp increase in 
incidence with age which continues to rise after the age of 50 but at a somewhat 
slower rate. In Japan, however, there is a similar increase in rate of increased 
incidence but at the age of 50 incidence plateaus and even goes down with age (see 
fig. 3) (3). A similar pattern is seen in women from the USA and Denmark with 
oestrogen receptor (ER) negative breast cancer (3). This suggests that the type of 
breast cancer most prevalent in Japan is different to that in Europe and the USA. ER 
negative breast cancer may therefore be more associated with deprivation while ER 
positive breast cancer is associated with affluence and adoption of the Western 
lifestyle. In addition, geographical variation between countries suggests that genetic 
factors may also play a part.
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Breast cancer incidence among US White, Japanese Hawaiian, Japanese women 
during three time periods: 1993-97, 1983-87, 1973-77
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Fig 3: Age specific incidence rates for US white women generated from nine SEER 
registries. Rates for US Hawaiian Japanese and Japanese (Miyagi) women 
abstracted from lARC Cancer Incidence in Five Continents (1993-97, 1983-87, 
1973-77)
1.2 Worldwide trends in survival
Despite the high incidence in the West, it is women from developing countries who 
have a higher mortality from breast cancer. In the USA, Australasia and Northern 
Europe breast cancer mortality has consistently been in decline since at least the 
early 90’s and this decline is most marked in the over 50 age group (2). Prior to this 
(from the 1950’s onwards) there had been a general increase in mortality. These 
improvements are in part due to the introduction of breast screening, however, 
similar trends are seen in the younger age groups so breast screening does not 
explain all of these changes. Conversely in countries which had a relatively low rate 
of breast cancer incidence in Eastern Europe, for example the Russian Federation, 
Estonia, Romania and Hungary, there has been as increase in mortality (2). Again, 
epidemiological data for developing countries is somewhat sparse due to the lack of 
cancer registries. However, from what is available, it is evident that mortality has 
remained the same and in some places increased (2).
Natasha C Henley, 2006 20
Introduction
The reasons for these wide variations are not immediately obvious. Part of the 
reason may be that women from developing countries present with advanced disease 
and they are less likely to be diagnosed at breast screening because there are no 
breast screening facilities. However, improvements in breast cancer mortality are 
seen throughout all age groups in affluent countries suggesting that breast screening 
does not explain all of these temporal trends. The availability of ti'eatment may also 
explain some of the differences in mortality, however, even within developing 
countries there appears to be a difference between how well affluent and deprived 
women do following a breast cancer diagnosis. This leaves differences in 
environmental and aetiological factors as the remaining explanation for survival 
differences (see later). It is interesting to note that the pattern of incidence of breast 
cancer in Asia (see fig 3) with a decline in later age mirrors that of ER negative 
breast cancer in the USA (2). The explanation for the difference in mortality may 
therefore be that women from less developed countries are developing ER negative 
tumours.
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2. Breast cancer incidence and mortality in Scotland
The incidence of breast cancer in Scotland is similar to the rest of Europe. While 
incidence is higher in Scotland compared with Southern Europe, it is lower than 
USA. However, mortality from breast cancer in Scotland is worse than USA (fig 4). 
Similar to the rest of the world, the incidence and mortality for breast cancer in 
Scotland varies with socio-economic status. It has been consistently shown that, 
independent of stage at presentation although deprived women in Scotland have a 
lower incidence of breast cancer than affluent women, they do consistently worse 
than more affluent women(8;10) (fig 5). In particular the levels of deprivation in the 
West of Scotland are higher than the rest of the country (11) which makes Scotland a 
good place to study the effects of deprivation on breast cancer incidence and 
mortality.
Incidence*
S c o h a n d  * 
E ng land  a n d  W ales  ^
Sweden
N eth e rlan d s
Italy
G e r m a n y
F inland
D enm arkUSA^
R ate  p e r 100 0 0 0  popu la tion
Mortality*
R »t«  p e r  100 000  popu lation
Survival**
%  surv ival a t  5  y e a rs  a f te r  d ia g n o s is
Fig 4: International comparison of incidence, mortality and survival from breast 
cancer with 95 % confidence intervals (12)
* Age-standardised rates per 100, 000 person years at risk (world standard 
population)
**Relative survival at 5 years, patients diagnosed 1985 -  1989
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2.1 Measuring Deprivation in Scotland
Deprivation and health are intrinsically linked. Indices of deprivation are important 
in analysing cancer registries for the effect of deprivation on health. They are also 
used to detennine the allocation of resources by local, regional and central 
government to health boards and primary care. Several indices are in routine use.
The commonly used scores are the Townsend score, favoured in England and Wales 
and the Carstairs score, favoured in Scotland. Both are based on various census 
variables, to a varying degree, however the Carstairs score was designed specifically 
to determine deprivation in Scotland (13).
The Carstairs and Morris score focuses on material deprivation in individual 
geographic localities. Census based variables for postcode sectors are determined 
and given a score. Postcode sectors are postcodes that are the same apart from the 
last two characters. The scores were originally described by Carstairs and Morris as 
a measure to reflect access to “those goods and services, resources and amenities and 
of a physical environment which are customary in society” (13). The 2001 version 
of the Carstairs score used the following variables: overcrowding (the proportion of 
people living in private households with a density of more than one person per 
room); male unemployment (the proportion of economically active males seeking or 
waiting to start work); low social class (the proportion of people in private 
households with an economically active head with head of household in social 
classes IV or V); ownership of a car (the proportion of people in private households 
which do not own a car) (14). These variables were selected because they have been 
shown to be highly coiTelated with one and other. The resulting score is then divided 
into 7 deprivation categories or “dep cats.” The dep cat is therefore a measure of the 
population’s relative material deprivation rather than an individual’s circumstances.
Deprivation indices identify geographic areas of deprivation rather than identifying 
individual circumstances. This has been a criticism of them because they examine a 
heterogeneous group of people rather assessing individual circumstances. In urban 
areas, where the geographic area is relatively small, the social circumstances of the 
population are usually more homogenous. However, in rural areas there can be wide 
variation within enumeration districts with relatively deprived areas next to affluent
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ones. A further criticism of deprivation indices based on the census is that they can 
only be updated every ten years; this has led to the development of scores which are 
not based on the census. However, the recent update of the Carstairs scores for 
Scotland has shown that there has not been a significant relative change in the socio­
economic position of individual small areas (14) Despite these criticisms deprivation 
indices are extensively used for planning the allocation of resources to health boards 
by local, central and regional government.
2.2 Deprivation and Health in Glasgow
Deprivation has long been associated with poor health outcomes; both in self 
reported health measures as well as more subjective measures such as death rates. In 
the UK, between 1991-1995, men of social class 1 had a 9.5-year better life 
expectancy than men in social class V (the difference was 6.4 years in women). 
People of lower social class are more likely to die of diseases such as coronary artery 
disease and lung cancer (15). Scotland itself has higher mortality rates than 
England (16). However, differences in levels of deprivation between Scotland and 
England alone do not explain this difference. The gap in deprivation between 
Scotland and England actually nanowed between 1981 and 2001 but differences in 
mortality actually increased (16). While genetic differences between Scotland and 
England may be a possibility, it is unlikely that this entirely explains the mortality 
difference. It is more likely that this difference is due to Scottish people in an 
equivalent deprivation category to their English counterparts experiencing greater 
personal health risk.
In Scotland, a higher proportion of people suffer ill health compared with the rest of 
the UK. However, it appears that this poor health is not only a result of the health 
disadvantage from simply being deprived, it is also a result of the individual health 
behaviour of individuals. In Scotland, alcohol consumption is greater than the rest of 
the UK and smoking is more prevalent. In addition, there are lower levels of 
physical activity (16). The incidence of smoking is highest amongst the most 
deprived although paradoxically alcohol consumption is highest in the least deprived 
women (15). Therefore, levels of deprivation as well as the “Scottish Effect” have 
resulted in Scotland as a whole lagging behind England and Wales in terms of
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improvements in health and mortality. This puts the deprived people of Scotland at 
even more disadvantage than the rest of the UK population in terms of survival.
Greater Glasgow contains eight of the ten most socio-economically deprived 
electoral wards in Scotland (17), as well as the nine of the ten worst off UK 
parliamentary constituencies, in terms of health (11). Compared with the rest of 
Scotland, Glasgow has the lowest life expectancy for both women and men.
Incidence of ischaemic heart disease, smoking, hypertension, obesity and lung 
cancer, which are all associated with deprivation, are all above the national average 
(18). The levels of deprivation in Glasgow and the disparities between rich and poor 
within Glasgow itself (17) make it an ideal place to study the effects of deprivation 
on population health.
While it is not surprising that there should be differences in mortality in the diseases 
associated with socio-economic deprivation such as cardiovascular disease and lung 
cancer, what is surprising that disparities exist in mortality for cancers not associated 
with smoking, alcohol intake, obesity and lack of physical exercise. In fact, while 
the survival for many cancers has improved overall during the last 20 years, a gap in 
suiwival exists between affluent and deprived people and for some cancers it is 
actually widening. This gap persists even after correcting for widening differences in 
overall mortality between rich and poor (19). Delay in presentation or less effective 
access to healthcare may be responsible. Deprived patients tend to use NHS 
resources less, which may be due to the constraints of travel and childcare. In 
addition, affluent people may be more effective in communicating healthcare needs 
to their doctors.
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2.3 Socio-economic differences in breast cancer incidence in Scotland
Like the rest of the Western world, the incidence of breast cancer in Scotland is 
highest in the more affluent socio-economic groups (fig 6)(12). While data on 
changes in incidence by deprivation in Scotland are not available, data from the West 
Midlands has shown that incidence is continuing to rise in affluent women while 
remaining relatively stable in less affluent women (20) (fig 7).
In c id e n c e  by  d e p riv a tio n  q u in tile
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Fig 5: Differences in incidence for women diagnosed with breast cancer in Scotland 
by deprivation quintile using Carstairs scores between 1997-2001 (Data from ISD 
Scotland
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Fig 6: Variation in breast cancer incidence with deprivation in the period 1984 -  
1998 for women in the West Midlands health region. Incidence measured by 3 year 
rolling directly age standardised breast cancer incidence rates in women of all ages in 
Townsend band 1 (most affluent) and 5 (most deprived)(20)
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3 Reasons for socio-economic differences in incidence
3.1 Risk factors
The reasons why affluent women should have a higher incidence of breast cancer are 
not immediately obvious. It has been proposed that differences in their risk factors 
influence this dichotomy. Exposur e to oestrogen is thought to increase the risk of 
breast cancer. The exact mechanism for this is unknown. Oestrodiol is thought to 
promote mitosis of breast epithelial cells thereby increasing the chance of dysplasia 
and eventually carcinogenesis (21). Reproductive factors which increase exposure to 
oestrogen are: nulliparity; late age at first pregnaney; early menarche; late 
menopause; and hormone replacement therapy (HRT) use (22). Each of these factors 
is affected by varying degrees by socioeconomic status and may contribute to 
differences in incidence of breast cancer between socioeconomic groups.
Pregnancy itself causes a transient increase in the risk of breast cancer due to the 
high levels of oestrogen during the pregnancy but only if a malignant transformation 
is already present in the breast. However, in the longer term the risk for breast 
cancer is increased in women who are nulliparous (23). In addition, an early age at 
first pregnancy reduces the future breast cancer risk. Affluent women are more 
likely to be nulliparous and be older at first pregnancy. Education and higher social 
class has been consistently linked with later age at first live birth and nulliparity (4). 
Affluent women have also been shown to have a shorter duration of breast feeding 
which could potentially increase their breast cancer risk because duration of breast 
feeding has also been shown to be protective against breast cancer (24).
Early menarche also results in an increased breast cancer risk. For every one year 
delay in the onset of menstruation there is a 5% decrease in breast cancer risk. This 
effect is most marked in premenopausal women (21). Between the 19^ '^ and 20^ 
centuries there was a significant reduction in the age of menarche which was thought 
to reflect improved nutrition and environmental factors. However, in the last 20-30 
years the reduction in age of menarche has been modest, at about 6 months (25).
This probably explains why no socioeconomie difference has been demonstrated in
Natasha C Henley, 2006 28
Introduction
age at menarche between socioeconomic groups (4;25). Therefore, although age at 
menarche increases the risk of breast cancer it is unlikely to contribute to the 
socioeconomic differences in incidence.
Late menopause is associated with increased risk of breast cancer. The menopause 
causes a slow down in the increased breast cancer risk associated with aging (21). 
Socio-economic differences in the age of menopause have consistently been 
demonstrated regardless of the measure used. A recent study showed that material 
deprivation both during childhood and adulthood contributed to an early menopause 
(26). The reason for this difference is thought to be due to nutritional deficit in 
childhood leading to delayed growth and early menopause, while in adulthood 
behavioural factors such as obesity and smoking predominate. A later age at 
menopause in affluent women may also be contributing factors to socioeconomic 
differences in breast cancer risk.
HRT has recently been shown to increase risk of breast cancer. Use for 10 years and 
over accounts for an extra 19 cases of breast cancer per 1000 users of combined 
HRT (27). Use of HRT increases the length of time that breast tissue is exposed to 
oestrogen, thereby increasing the risk of breast cancer. HRT use has expanded 
rapidly since its introduction. However, affluent women are more likely to take HRT 
than deprived women (28). Therefore, differing patterns of HRT use between 
affluent and deprived women may account in part for socio-economic differences in 
incidence.
In addition to the reproductive factors which are thought to increase oestrogen 
exposure, obesity and dietary factors are thought to be linked to ineidence of breast 
cancer. Postmenopausally, adipose tissue is the main source of endogenous 
oestrogen. It is thought that in obese patients there is excessive production of 
oestrogen which predisposes to breast cancer. In fact, obesity only predisposes to 
increased breast cancer risk postmenopausally (21). In premenopausal women, the 
amenorrhea associated with pubertal obesity appears to be relatively protective from 
breast cancer (29;30). In addition, high birth weight and childhood malnourishment 
are associated with an increased risk of premenopausal breast cancer (31).
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It has been well documented that obesity is associated with material deprivation, both 
in adulthood and in childhood. The excess childhood obesity associated with 
deprivation might account for a lower incidence of premenopausal breast cancer in 
deprived socioeconomic groups. However, adulthood obesity in deprived 
socioeconomic groups contradicts the finding that affluent women have a higher 
incidence of postmenopausal breast cancer. This suggests that the relationship 
between socio-economic status and incidence of breast cancer is multifactoral and 
perhaps dietary factors are not as important as reproductive factors.
3.2 Breast Screening
Breast screening was first introduced in the UK in 1991. This resulted in a shaip rise 
in the incidence of breast cancer. The uptake of breast screening has progressively 
increased over time resulting in uptake rates of around 75% with a nationally agreed 
minimum standard of 70% (data from NHS breast Screening Programme). However, 
despite these high uptake rates social deprivation has a significant effect on the 
likelihood of attending for breast screening. Early studies carried out soon after the 
implementation of breast screening showed that there was a difference between 
socio-economic groups that was independent of distance from a screening centre 
(32;33). More recent studies have shown that this deprivation gap in attendance at 
breast screening persists despite efforts to improve attendance by targeting women 
from lower socio-economic groups (34;35).
The increased attendance at breast screening by more affluent women has resulted in 
a higher incidenee of breast cancer in this group of women. However, the 
introduction of breast screening alone should cause an increase in the incidence of 
breast cancer in the women who attend for screening as the prevalent round is 
completed. It would then be expeeted that that incidence would remain at a constant 
rate but at a slightly higher level. Data from the West Midlands (fig 6) has shown 
that incidence in the screening age group is continuing to rise even after the prevalent 
round of screening has been completed. Moreover, this rise appears to be specific to 
affluent women while the incidence in deprived women is remaining relatively 
constant (20). This suggests that although breast screening affects incidence in the 
short term by identifying prevalent tumours, the long term effects are not so clear
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cut. Breast screening appears to identify the slow growing tumours which would 
never have been clinically apparent. Affluent women are more likely to attend breast 
screening so this may contribute to the increased incidence of breast cancer in this 
group. However, what is unexpected is the continuing rise in incidence in affluent 
women, which suggests that the increased rate of incidence in affluent women must 
be due to factors other than screening, for example, aetiological factors.
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Fig 7: Variation in breast cancer incidence with deprivation in the period 1984 -  
1998 . Incidence measured by 3 year rolling directly age standardised breast cancer 
incidence rates in women aged 50-64 in Townsend band 1 (most affluent) and 5 
(most deprived) (20)
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4 Socio-economic differences in breast cancer survival in Scotland
Despite the higher incidence in affluent women disparities in survival exist between 
affluent and deprived women in Scotland. In England and Wales survival is 5.8% 
better in affluent women (19). The deprivation gap in Scotland is largely similar at 
6.6% (data from ISD Scotland -  see fig. 8).
These differences between socio-economic groups exist regardless of the way socio­
economic status is determined. Both area based measures (e.g. postcode) and 
individual based measures (e.g. social class) display the same relationship. It is 
difficult to assess individual socio-economic circumstances in large population based 
studies looking at trends in survival. This has necessitated the use of scores for 
geographic areas in order to assess survival trends over time. These tend to 
underestimate the actual size of the survival gap due to the assessment of 
heterogeneous groups of people. It was recently estimated that area based scores 
may underestimate the gap by up to 25 % (36). Therefore, the gap may be larger 
than estimated. In fact, socio-economic factors appear to ovenide other demographic 
factors known to be associated with poor outcome from breast cancer. Studies from 
the USA have looked at racial disparities in breast cancer survival have shown that 
white women consistently do better compared with African-American women (37). 
However in the USA race is linked inextricably with socio-economic status and in 
fact, when data on race in corrected for socio-economic status there is no difference 
between etlinic groups (38).
Several reasons for these persistent survival differences have been proposed. It is 
thought that deprived women present with more advanced disease than affluent 
women (9;39;40). It has also been shown that deprived women are less likely to 
attend for breast screening (32-35). There has also been a suggestion that treatment 
for deprived women is different from that of affluent women (41). However, even 
con ecting for these factors some of the survival difference cannot be accounted for 
and researchers have turned to other reasons to explain survival differences.
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Fig 8: Differences in 5 year survival by deprivation quintile for women diagnosed 
with breast cancer in 1997-2001 (Data from ISD Scotland)
4.1 Pathological Factors
4.1.1 Pathology and Prognosis of Breast Cancer
Breast cancer is staged in several different ways. The TNM staging is in common 
use (see table 1 ) and can be grouped in to stage 1 to IV using the International Union 
Against Cancer (UlCC) classification (see table 2). These different stages are 
important in determining prognosis.
The Nottingham Prognostic Index (NPl) can also be used to combine pathological 
factors to determine prognosis. It uses tumour size, lymph node stage (where stage 1 
is no nodes involved, stage 2 is one to three nodes involved and stage 3 is four or 
more nodes involved) and histological grade (Bloom and Richardson 1 -  111). These 
are combined to give the NPl:
NPl = 0.2 X size (cm) + lymph node stage + grade 
The NPl is then divided to give a score which determines prognosis(42) ( see table 3)
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Table 1;
Tis
XI
T2
T3
T4a
T4b
T4c
T4d
NO
N1
N2
N3
MO
M l
TNM Classification of breast tumours
Cancer in situ 
< 2 cm
>2 cm - <5 cm 
>5 cm
Involvement of chest wall
Involvement of skin (including ulceration, direct infiltration, peau
d’orange and satellite nodules
T4a and T4b together
Inflammatory cancer
No regional node métastasés
Palpable mobile involved ipsilateral axillary nodes
Fixed involved ipsilateral axillary nodes
Ipsilateral internal mammary node involvement (rarely clinically 
detectable)
No evidence of metastasis
Distant metastasis (includes ipsilateral supraclavicular nodes
Table 2: Correlation of TNM classification with UICC stage (1987)
UICC stage TNM Classification % 5 year survival
I T1,N 0,M 0 84
II T1,N 1,M 0;T2, NO-1, MO 71
III Any T, N2-3, MO; T3 any 
N, MO; T4,anyN , MO
48
I V Any T, any N, M l 18
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Table 3: Correlation between NPl and 15 year survival
Prognostic Group Index value 15 year suiwival
Good <3.4 80%
Moderate >3.4 <5.4 42%
Poor >5.4 13%
Many attempts have been made to attribute breast cancer survival differences 
between rich and poor to tumour pathology and stage at presentation, but none of the 
findings have been consistent. Deprived women may present with later stage 
tumours (9;40;43), especially in the older age group (6). Despite these differences in 
pathology, none of these studies have managed to account for all of the survival 
difference. In contrast, two studies showed that although deprived women 
experience worse survival than more affluent women there is no evidence that they 
present with later stage disease(44;45).
These conflicting reports suggest that while some of the differences in survival may 
be due to different pathology, other factors must be involved. The fact that deprived 
women might present with later stage disease may be due to a delay in presentation 
either on the part of the patient or in that they are deprived of healthcare seiwices. 
However, it has also been suggested that they may have higher grade disease (41) or 
hormone receptor negative disease (10) suggesting that deprived women are also 
developing more aggressive types of cancer.
4.2 Biological Factors
There is evidence that deprived women present with worse prognosis tumours in 
terms of histological grade (40;41) and ER status (10;46).
Tumour differentiation is scored and divided into three Bloom and Richardson 
grades. These grades predict survival, grade I having the best prognosis and grade 
III having the worst prognosis (47). Findings on the association between histological 
grade and deprivation have been inconsistent. Some of the larger studies that have 
identified survival differences between deprived and affluent women have not 
included an analysis on histological grade as information on grade as not available on
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all patients (9;10;45;48). However, two studies which analysed pathological 
differences between deprived and affluent women identified that deprived women 
were more likely to have high grade disease (40;41). Because these studies did not 
include data on survival it is difficult to assess the contribution of histological grade 
at presentation to survival differences. Two studies based on patients in the West of 
Scotland showed that there was no difference in histological grade between 
deprivation groups (44;49). However, the proportion of patients in these studies who 
had information available on histological grade available were small which makes 
the findings less reliable.
Breast cancers can be divided into hormone sensitive and hormone insensitive 
tumours. The routinely measured hormone receptors are oestrogen and progesterone. 
Oestrogen receptor (ER) positivity determines response to endocrine therapy such as 
tamoxifen (an oestrogen antagonist) or the more recently available aromatase 
inhibitors. Treatment with tamoxifen reduces the chances of local recunence by 
around 50% at 5 years and improves 5 year survival by around 25% in ER positive 
but not ER negative patients (50). ER positivity per se does not confer a survival 
advantage however it detennines the response to tamoxifen which reduces the chance 
of recurrence and by extension improves mortality(51 ;52). Progesterone receptor 
positivity also gives a survival advantage(51) and although there is no therapeutic 
way of manipulating the progesterone receptor directly there is evidence that 
ER+/PR- tumours are more likely to be tamoxifen resistant than ER+/PR+ tumours 
(53).
The association between hormone receptor positive breast cancer and affluence is 
also contentious. Two studies have shown that low income and deprivation are 
associated with ER negative breast cancer (10;46). Thomson et al.(lO) calculated 
that the difference in proportion of ER positive tumours between derived and affluent 
patients only accounted for 10% of the survival gap. Other studies have attempted to 
show that affluence is associated with hormone sensitive breast cancer but have 
failed to do so (41;44). There is therefore a suggestion that differences in hormone 
receptor status may have an influence on the survival difference but other factors are 
inevitably involved.
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4.3 Treatment factors
4.3.1 Primary Care
Diagnostic delay in breast cancer results in reduced survival (54). The delay may be 
on the part of the patient in that they ignore breast symptoms or it may be that the 
way that primary care is delivered results in diagnostic delay (e.g. long waiting times 
for appointments with the general practitioner). It has not been shown consistently 
that deprived women wait longer before seeing their GPs with breast symptoms than 
affluent women. A meta-analysis of studies of reasons for diagnostic delay showed 
that the only factor consistently associated with delay in presentation to primary care 
was older age. The evidence for low income being associated with delay in 
presentation was only moderate (55).
In terms of provider delay there does not appear to be a socio-economic gradient. 
There is no difference in waiting times for referral between affluent and deprived 
women. In fact, following diagnosis, deprived women appear to consult their general 
practitioners more frequently than affluent women (56). Therefore, delivery of 
healthcare at the primary level does not appear to be a factor.
4.3.2 Secondary Care 
Surgery for breast cancer
The mainstay of treatment for breast cancer is surgery, either with breast 
conservation surgeiy or mastectomy with axillary staging. If a woman has a 
mastectomy they also have the option of immediate or delayed reconstruction. Until 
the early 70’s, the modified radical mastectomy, as described by Halsted (57), was 
the only surgical treatment for invasive breast cancer. Over the years since it was 
first described there were a few minor modifieations involving excision of the 
internal mammaiy nodes (58) or preservation of the pectoral muscles (59). Changes 
were made to the extent of lymph node dissection but essentially the extent of 
surgery remained largely unchanged.
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Breast conservation surgery with adjuvant radiotherapy was compared with 
mastectomy in two randomised controlled trials in the 70’s. Five year follow up 
suggested no survival difference between the two treatment modalities (60;61). 
Comparison of outcome at 20 years again confirmed that there was no survival 
difference between the two procedures. The only disadvantage was that in 
conserving the breast there was a higher risk of local recurrence but this did not 
affect survival (62;63). Several other randomized controlled trials confirmed these 
findings (64-66). These trials were limited to patients with small tumours (less than 
5 em) and four relative contraindications to breast conservation surgery have since 
been identified. (1) or 2"  ^trimester of pregnancy (2) history of previous 
therapeutic irradiation of the breast (3) multifocal disease (4) extensive 
microcalcifications seen on mammography. Other relative contraindications were a 
large tumour in a small breast that would result in an acceptable cosmetic 
outcome(67).
Despite the extensive evidence that conservation is as effective as mastectomy and 
the recommendation of conservation for early stage breast cancer, uptake of 
conseiwation surgery has not been unifonn. Based on figures from the United States, 
it has been estimated that 10% of tumours smaller than 2cm and 30% of tumours 
between 2cm and 5cm require mastectomy due to a medical contraindication (68). 
Despite the guidelines, studies have shown rates of conservation to be widely varied. 
Some studies have reported rates as low as 15% (69) while others have reported rates 
as high as 85% (70). In addition, data published on mastectomy rate from the recent 
AT AC trial showed wide geographical variation in mastectomy rate of between 20 
and 97% (71).
The reasons behind these wide variations in mastectomy rate are not entirely clear. 
The international differences suggest that some of the reasons might be cultural but 
variation is also seen within countries. It may be the way that treatment options are 
presented to the patients, they may be presented in a biased manner or the option of 
conservation surgery is not presented at all (69). Older, male surgeons as well as 
surgeons with a smaller caseload (39) are also less likely to recommend conservation 
surgery . In addition, race and socio-economic status also appear to be important in 
determining surgical management (72) . The surgeons recommendation has been
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shown to be of primary importance in determining surgical management (73;74) so 
physician factors are probably more important than demographic factors. Although 
if this is the case, there might be the uncomfortable implication that surgeons are in 
some way be responsible for the demographic differences because they treat women 
from different backgrounds differently.
Differences in surgical management between socio-economic groups
Many studies from the USA have shown that women of lower socio-economic status 
are more likely to have a mastectomy, independent of tumour characteristics 
(38;72;75-77). Mastectomy is a slightly cheaper surgical option because it does not 
include the added expense of adjuvant radiotherapy. However, it is difficult to 
extrapolate these findings to the UK where healthcare is not paid for directly by the 
patient. Findings in the UK have been less consistent. There have been two studies 
showed that deprived women are more likely to have a mastectomy (10;41) but in 
both of these this was not the primaiy outcome that was being examined in the 
studies. A study from Denmark, where healthcare is state provided, also found that 
there was a difference between affluent and deprived women in surgical management 
(78). On the other hand a study of women in Glasgow showed that there was in fact 
no difference (49). It appears therefore that, while some of the reason that deprived 
women should tend to have more mastectomies, independent of tumour stage, is 
related to the actual monetaiy cost, there must be other reasons as well.
In studies looking at factors involved in choosing surgical management, the excess 
cost of travelling to and from a radiotherapy centre and the cost of childcare have 
been identified as important in persuading women to have a mastectomy (79;80). 
Both of these studies were conducted in the USA and the cost of healthcare being 
largely borne by the patients may be a confounding factor in these two studies. The 
additional finding in a study by Morrow et al (81) that income also influences use of 
reconstruction suggests that it is the financial cost which is most important. Whether 
financial factors influence choice of surgery in the UK to such an extent is not clear. 
However, if the recommendations of the surgeon supersede these reasons (72;73), 
perhaps the way treatment options are presented to the patient are not entirely 
impartial.
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It is important to not only understand why there is such wide variation in mastectomy 
rate but also why certain groups of patients are more likely to have a mastectomy 
than others. Initially, it was thought that having a mastectomy did not cause 
psychological morbidity and early studies showed no difference between women 
treated with the two types of surgery (82). It was thought that the lack of difference 
was due to patients’ concern about recurrence using the less radical technique. 
However, a more recent prospective study with 5 year follow up has shown that 
conservation surgery is associated with better body image and better function in 
terms of work and hobbies. This difference was noted across the age groups.
Quality of life scores improved over time for the conservation surgery patients but 
not the mastectomy patients (83). This implies that it is important to ensure that 
conservation surgery is offered to anyone who is eligible regardless of age or other 
demographic factors.
Despite the psychological co-morbidity of having a mastectomy, having a choice 
between conseiwation surgery and mastectomy actually results in lower levels of 
anxiety and depression (84). It has been shown that deprived women have been 
shown to adopt a passive role in decision making for breast cancer (85). Whether 
this passive role is due to patient choice or a more “paternalistic” attitude on the part 
of the surgeon where they are not actually offered a choice of surgery is unclear. 
When asked, patients, regardless of socio-economic status, tend to prefer a more 
collaborative role in decision making where their opinions and preferences are taken 
into consideration by the surgeon (86). In addition, a recent study in Glasgow on the 
information given to women with breast cancer showed that deprived women 
received less information than their more affluent counterparts and had higher 
anxiety scores when tested several years following completion of treatment (87). 
Thus, if deprived women are having more mastectomies because they are being 
denied the choice of surgery rather than due to clinical need, they may well have 
excessive psychological co-morbidity not only due to the type of surgery but also the 
lack of choice. It also appears that it is the surgeons themselves may be contributing 
to this psychological co-morbidity, particularly in deprived women. While 
psychological co-morbidity does not translate into survival differences, it has 
implications for quality of life.
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4.3.3 Breast Screening
Socio-economic inequalities in breast cancer exist not only in treatment but also in 
uptake of breast screening. It is well known that deprived women are less likely to 
attend breast screening(33). In Greater Glasgow the uptake for breast screening in 
the period 1999-2000 -  2001-2003 was 67% compared with a Scottish average of 
75% (data from ISD Scotland). The Glasgow uptake rate falls short of the national 
standard of more than 70 % set by the National Health Service Breast Screening 
Programme (NHSBSP). Part of this deficit is probably a reflection of the high levels 
of deprivation in Glasgow. For Scotland as a whole the uptake in dep cat 7 is below 
60% compared with just over 80% in dep cat 1 (data from ISD Scotland -  see fig 9).
3 4 5
Deprivation Category
Fig 9: Uptake of breast screening in Scotland by deprivation category (data from 
ISD Scotland)
It is not clear whether these differences in uptake of screening translate into survival 
differences between rich and poor and whether they have exaggerated the previously 
described survival differences. Screen detected tumours have a better prognosis at 
diagnosis than those that present symptomatically because they tend to be smaller 
(88) and have a better prognosis (33). This improved prognosis is seen among all
Natasha c  Henley, 2006 41
Introduction
levels of deprivation, however, with the different uptake of screening between more 
and less well off women, it might be expected that breast screening would compound 
the existing survival differences. In fact, a study of the Northern and Yorkshire breast 
cancer registry showed that there were strong gradients of stage and grade between 
socio-economic groups and this difference was particularly marked in the breast 
screening age group (40). From this study it appears that breast screening may have 
actually caused a widening of the deprivation gap, but without any data on survival it 
is difficult to draw any finn conclusions from this.
There is some limited data available on trends in mortality between socio-economic 
groups since the introduction of breast screening but it gives conflicting results. A 
recent study based on patients in Glasgow looked at the pathological and survival 
differences between a group of patients diagnosed in a year prior to the start of the 
NHSBSP and following the institution of the NHSBSP. They noted a difference in 8 
year survival between the most and the least affluent of about 10% in both the pre- 
and post- breast screening cohorts of patients, despite an overall increase in survival 
of about 10% (89). This suggests that breast screening has improved outcome for 
all women rather than being selectively beneficial for affluent women. Data from the 
West Midlands has suggested that the deprivation gap is actually closing between the 
most and least affluent. They found that the difference in 5 year survival between 
most and least affluent women was 12% for women diagnosed between 1984 and 
1988 but the gap had narrowed to 8% for women diagnosed in 1994-1998 (20). It is 
therefore difficult to know whether the breast screening programme is contributing to 
or improving disparities in outcome. Clearly, with this lack of data on survival 
differences in the post-breast screening era, it is important to re-examine what impact 
breast screening has had.
4.3.4 Health Board
Geographical variation also appears to contribute to inequalities in breast cancer 
outcome. Several studies have shown that geographical variation exists between 
different health boards, in Scotland, (90) or health authorities, in England and Wales, 
(48). Health authorities with higher levels of deprivation appear to have worse 
outcomes from breast cancer but not all of the difference is explained by deprivation 
alone. This suggests that perhaps it is not deprivation alone that is resulting in poorer
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outcome for women from the under-performing health boards/ authorities, but the 
way that cancer services are provided and delivered. If there is variation between 
health authorities/ boards this might compound socio-economic inequalities.
The surgeons operating within each health authority may also be contributing to 
geographical differences. Previously, it has been shown that the degree of 
specialisation and the caseload of the operating surgeon influence breast cancer 
survival (91;92). More recent data however, has shown that the specialisation of the 
surgeon does not make any difference to 10 year survival (89), so the surgeons alone 
are not causing the differences between health boards. While deprivation does play a 
role in geographical variation in 10-year survival, there are clearly other factors in 
health care delivery, such as operating surgeon and availability of adjuvant therapy, 
that also play a role. With the introduction of multidisciplinary team working and 
more unifonn prescribing of adjuvant therapy some of these geographic differences 
and should be removed and perhaps by extension some of the differences between 
socio-economic groups.
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5. The Systemic Inflammatory Response, Deprivation and Breast 
Cancer
Clearly there are many factors that might contribute to differences in outcome 
between socio-economic groups. These centre around treatment factors and 
pathological factors. However, the way that the host responds to the tumour may 
also have an effect on outcome. Recently, the presence and magnitude of a systemic 
inflammatory response to cancer has been identified as prognostic in patients with 
malignancy. Recent work has suggested that the magnitude of the response varies 
with the type of tumour and can predict recurrence, cancer specific and overall 
survival, independent of clinical stage (93). In addition, recent studies have also 
shown that people from deprived socioeconomic groups have a raised “background” 
systemic inflammatory response (94;95) and it has also been suggested that they may 
have an elevated systemic inflammatory response to cancer which may account for 
their poorer cancer suivival (96).
The Systemic Inflammatory Response
The systemic inflammatory response occurs in the presence of tissue injury. For 
example, it occurs in response to infection, trauma, surgery, bums, tissue infarction, 
various immunologically mediated and crystal-induced inflammatory conditions as 
well as cancer. Following tissue injury there is a release of pro-inflammatory 
cytokines, which then induce an acute phase protein response. These are 
predominantly IL-6, IL-lp and TNF-a, IFNy, TGFp and IL-8. These are released 
from a variety of cells but macrophages and monocytes are the most important, while 
11-6 is the most important cytokine in indueing the production of the acute phase 
proteins by the hepatocytes of the liver. IL-6 was initially identified in B-cells but it 
is also produced by T cells, endothelial cells, macrophages and epithelial cells. 
However, the cytokines do not simply act as a cascade to induce the production of 
the acute phase proteins they also act as a network. Thus there is a complex 
interaction between the pro-inflammatory cytokines, with 11-6 as the most important, 
which result in the acute phase protein response (97).
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The acute phase response is characterised by the release of the acute phase proteins, 
the most marked response coming from C-reactive protein and Serum amyloid A. 
These have therefore become the prototypical serum markers of the acute phase 
response. C-reactive protein has the advantage over serum amyloid A in that there 
are defined standards on how to measure it, it is a more stable molecule, has no 
diurnal rhythm and is not altered in the fasted and fed states (97). Moreover, GRP 
testing is cheap and widely available. It is therefore C-reactive protein which is used 
in routine clinical practice as a marker for the systemic inflammatory response.
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Fig 10: Changes in plasma concentration of the acute phase protein in response to an 
inflammatory stimulus (97)
The signalling pathway in the hepatocytes which induces the production of C- 
reactive protein mRNA involves IL-6 binding to its receptor (IL-6Ra). IL-6Ra then 
forms a complex with the signal transduction molecule gp 130. This then further 
activates and phosphorylates the JAK kinases, which in turn activate C/EBPp and 
STAT 3, resulting in the production of C-reactive protein mRNA. Levels of IL-6 in 
the serum and levels of C-reactive protein are correlated with one another both in 
cancer patients (98) and in patients with cardiovascular disease (99).
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C-reactive protein was first discovered in the serum of patients with pneumococcal 
pneumonia. It was so named because it reacted with the pneumococcal C 
polysaccharide (97). Despite the fact that it was discovered almost 80 years ago its 
exact functions are not well known. The acute phase reactants are thought to limit 
tissue damage. C-reactive protein has been shown to have several functions in vivo. 
It acts as a scavenger molecule opsonising bacteria, fungi and parasites. It also binds 
neutrophils and macrophages and can activate the classical complement pathway
(100). While a systemic inflammatory response is advantageous when there is tissue 
injuiy, in patients with cancer, a systemic inflammatory response can be detrimental.
The Systemic Inflammatory Response and Cancer
The systemic inflammatory response appears to be important in the development and 
progression of neoplasia and appears to modulate the hypermetabolism, cachexia and 
malnutrition associated with cancer. The acute phase response results in the 
reprioritisation of hepatic protein synthesis to produce the acute phase reactants.
This in turn results in decreased production of the essential amino acids and the 
breakdown of skeletal muscle. A similar response is also seen in infection and 
trauma. While in the presence of infection the presenee of this response is beneficial 
and may aid tissue repair, blood clotting, prevent ongoing tissue damage and destroy 
infective organisms, its role in cancer is not known, hi patients with cancer it results 
in increased energy expenditure and accelerated weight loss and its presence is 
associated with a poor prognosis (101).
IL-6 has been implicated as important in the induction of the acute phase response to 
cancer. In a variety of cancers IL-6 is released from both the cancer cells themselves 
and the neighbouring tissues (98). The effects of IL-6 itself on tumour growth 
appear to be variable. It exhibits both autocrine and paracrine effects on tumour 
cells. In vitro studies have shown that it can be inhibitoiy or it may promote tumour 
growth. Results from in vivo models have been equally conflicting and the result 
appears to depend on the model used (102). An elevated serum IL-6 has been 
demonstrated in patients with a variety of solid tumours (98; 103-106) although its 
ability to predict prognosis independent of pathological variables has been 
inconsistent (104; 106-108).
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IL-6 appears to be related to the nutritional status of the patient with advanced 
cancer. In animal models administration of IL-6 results in an acute phase response 
associated with anorexia, weight loss and increased protein and fat breakdown (101). 
However in humans an elevated IL-6 has only been shown to associated with an 
acute phase protein response and malnutrition in patients with lung and colorectal 
cancer as well as lymphoma (101; 109). A significant amount of IL-6 is also 
produced peripherally in the tissues which may not be measured by serum estimation
(101). Thus although IL-6 is clearly important in the induction of the acute phase 
protein response to cancer it probably does not act independently but acts as part of a 
network of cytokines (which includes II-Ip and TNF-a, IFNy, TGFp and 11-8), 
Measurement of IL-6 in the serum does not correlate well with prognosis or 
malnutrition associated with cancer.
C-reactive protein is elevated over 1000 fold in the acute phase protein reaction. An 
elevation in the concentration of C-reactive protein is produced in response to 
increased elaboration of IL-6 either by inflammatory cells or tumour cells. In 
patients with colorectal, pancreatic, gastric and lung cancer a raised C-reactive 
protein has been shown to be associated with a reduced cancer specific and non­
cancer specific survival, which is independent of stage at presentation (93). While 
the end product of a raised systemic inflammatory response is the cachexia and 
malnutrition associated with cancer, the reason why some tumours should induce an 
enhanced inflammatory response more than others is not clear.
The tumour cells themselves may be capable of producing their own cytokines which 
may promote tumour growth and proliferation. In turn these cytokines induce the 
systemic inflammatory response and its sequelae, making this a tumour derived 
response. Alternatively, the production of cytokines may come from the injured 
tissues making the systemic inflammatory response a host derived response. In fact, 
in colorectal cancer a poor lymphocytic infiltrate is associated with a poor prognosis 
and an enhanced systemic inflammatory response (110), suggesting that the tumours 
themselves produce their own cytokines rather than the surrounding tissues. While 
in renal carcinoma greater lymphocytic response is associated with a raised systemic
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inflammatory response and a poor prognosis (111), suggesting that it is the 
surrounding tissues that produce the inflammatory response.
The Systemic Inflammatory Response and Breast Cancer
Breast cancer does not tend to be associated with nutritional depletion and weight 
loss, except in its latter stages, in the same way as pancreatic, gastro-oesophageal or 
colorectal cancer. Thus the systemic inflammatoiy response in breast cancer has not 
been as well characterised as in the more “inflammatory” tumours and results have 
been less consistent.
For this same reason the inflammatory response has been studied in patients with 
metastatic breast cancer more than those with primary disease. Serum IL-6 has been 
shown to be raised in patients with breast cancer more than in healthy controls and it 
is also raised in patients with metastatic disease more than those with only loco- 
regional disease (112). A raised serum IL-6 predicts poor prognosis (102;113-115) 
in metastatic breast cancer as well as response to chemotherapy (115). In addition it 
also predicts the number of sites of métastasés (102) suggesting that the magnitude of 
the host response is associated with the extent of disease. What is not known is if a 
raised IL-6 predicts outcome in patients with primary breast cancer.
The role of the systemic inflammatory response, as reflected in a raised CRP has not 
been fully elucidated in breast cancer. A raised CRP has been demonstrated in 
patients with locally invasive and ulcerating breast tumours but not in patients with 
earlier stage disease. In this study the presence of a systemic inflammatoiy response 
did not predict survival (116). Patients with metastatic disease have been included in 
studies of a heterogeneous group of patients with solid tumours which showed that 
the systemic inflammatory response predicted survival (93;117). However, only one 
study has assessed the relationship of the systemic inflammatory response to survival 
in breast cancer. This study looked at patients with metastatic disease and showed 
that semm CRP combined with serum albumin predicted survival (118). What is not 
known is how the systemic inflammatory response relates to survival in primary 
disease.
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The systemic inflammatory response and deprivation
There is some suggestion that people from lower socio-economic groups have a 
greater systemic inflammatory response to cancer compared with the more affluent.
In healthy subjects, higher levels of socio-economic deprivation are associated with 
an enhanced inflammatory response. For example, measurement of background 
levels of C-reactive protein in randomly selected male subjects has shown that socio­
economic deprivation is related to a higher level of C-reactive protein, after adjusting 
for smoking, waist-to-hip ratio and prevalence of other diseases(94;95). C-reactive 
protein is known to be raised in a number of disease states, particularly in cardio­
vascular disease, obesity and smoking (119). Both of these have a higher incidence 
in people of lower socio-economic status, and may account for why they have a 
raised C-reactive protein compared with people of higher socio-economic status.
There is some evidence in colorectal cancer that a difference in the magnitude of 
inflammatory response might account for survival differences between socio­
economic groups. Patients with colorectal cancer who had a raised preoperative CRT 
were shown to have a worse eancer specific and non-cancer specific survival. In 
addition deprived patients had a worse non-cancer specific survival (96). While 
there was no direct link between a raised CRP and deprivation in this study, a raised 
CRP in deprived patients appeared to account for the effect of deprivation on cancer 
survival.
Whether this relationship exists in breast cancer is not clear. A recent study has 
shown that deprived women with breast cancer have a raised pre-operative C- 
reactive protein compared to more affluent women. This rise was not related to 
tumour stage at presentation (120). This study used standard laboratory C-reactive 
protein with a sensitivity of >6mg/l. Data was not available on survival so it is not 
clear whether this raised inflammatory response was related to survival. It does 
however pose the question that perhaps the systemic inflammatory response might 
contribute to survival differences observed between affluent and deprived women.
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6. Summary
A paradox appears to exist in breast cancer survival and incidence. While affluent 
women are more likely to develop breast cancer, deprived women tend to die of the 
disease. These findings have not been consistent in all studies but it does appear to 
be a general trend. Several factors have been suggested for the reason behind the 
deprivation gap: tumour pathology, honnone sensitivity, treatment both in primary 
and secondary care, access to breast screening and the way that breast cancer 
services are provided. A further more novel reason for survival differences may be 
in the nature of the systemic inflammatory response to breast cancer by deprived and 
affluent women. This has never been demonstrated in breast cancer but has been 
suggested in colorectal cancer.
Many of the studies examining the deprivation gap were carried out prior to the 
introduction of breast screening. Breast screening has increased the incidence of 
breast cancer overall but appears to have increased it more in affluent women. This 
may have influenced the presence and magnitude of the deprivation gap but there 
have been few studies examining this.
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Aims
The thesis aims to examine, in a population of patients with breast cancer in the post 
breast screening era, if a deprivation gap in survival persists. Furthermore, it will 
assess what potential reasons may underlie a survival difference, if it exists.
The first chapter will establish whether the deprivation gap still exists in Glasgow in 
terms of survival from breast cancer. Using the Greater Glasgow Breast Cancer 
Audit database, which has over 5 year follow up for patients undergoing surgery for 
primary operable breast cancer, survival will be analysed to see if deprivation has 
any influence on it. Other factors such as pathology and treatment will also be 
examined to see if they affect outcome.
Although there is no differenee in survival between patients undergoing mastectomy 
compared with conservation surgeiy, it is accepted that overall breast conservation 
surgery is underutilised. One of the factors that may be contributing to this is 
deprivation. The second chapter will assess if the mastectomy rate in Glasgow is 
higher than reported in the literature and to what extent deprivation contributes to 
this.
The risk factors associated with ER positive breast cancer are known to be more 
prevalent in affluent women and ER positive breast cancer carries a better prognosis. 
Over time the risk factors associated with ER positive breast cancer have increased 
but more rapidly in affluent women. The third chapter will assess if there has been 
an increase in ER positive breast cancer over time and whether this increase has been 
more pronounced in affluent women, which might account for some of the suiwival 
differences.
Finally the host systemic inflammatoiy response will be examined as a potential 
contributing factor to survival differences. Firstly, if the presence of the systemic 
inflammatory response predicts survival in breast cancer and also whether there is a 
difference in magnitude between affluent and deprived women.
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Chapter 1
Does the deprivation gap in breast cancer still exist? 
Introduction
It has long been established that there is a deprivation gap in survival from breast 
cancer (5;6; 10; 19). Evidence that women from deprived areas present with more 
advanced disease has been inconsistent (40;44;45;49). The uptake of breast 
screening is certainly worse in women from more deprived areas (32-35), while this 
may have affected the incidence in affluent women, it is not clear how this has 
impacted on survival differences.
There also remains persistent geographical variation in survival (8;48;90), although a 
recent study in Scotland has suggested that this variation has improved since the 
introduction of breast screening and multi-disciplinary team working (89). 
Geographical variation may exacerbate socio-economic differences if  the areas 
concerned are homogenous in terms of deprivation. The reason that geographical 
variation exists may be due to differences in socio-economic status of the population 
or, more concerning for clinicians, it may be that there is inequality in the provision 
and delivery of healthcare. There has also been a suggestion that surgery for breast 
cancer has not been performed adequately in the past and there is a survival 
advantage to being treated in a specialist breast unit (91;92;121;122).
The “deprivation effect” has been described extensively in previous studies in groups 
of women before the establishment of breast screening. However, with the 
establishment of breast screening, patients were treated in dedicated breast units and 
their treatment was determined by the multidisciplinary teams. The benefit of this is 
that healthcare provision should become more equal between socio-economic groups 
and between geographical areas and should therefore limit the deprivation gap.
With this in mind, the Greater Glasgow Breast Cancer audit was set up. A 
multidisciplinary cancer network of specialist breast units was established in Greater
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Glasgow. This network identified minimum standards of treatment in an attempt to 
standardise it and also to try to redress the balance between the treatment that women 
from different areas were receiving. Minimum standards were identified in surgical 
treatment, pathological assessment of the resected tumour and post-operative 
adjuvant therapy. All patients were managed by specialist breast teams in specialist 
clinics all under the umbrella of a managed clinical network. All data on patients 
was collected prospectively and held by the Greater Glasgow Health Board. Results 
were intermittently audited to ensure standards were being maintained and the breast 
units were being compliant.
The establishment of managed clinical networks (MCN) was championed by the 
Caiman Hine report (123) which was published around the time that the Glasgow 
Managed clinical network was established. However, the Glasgow MCN was the 
first example of an MCN in Scotland.
As part of the follow up to the establishment of the MCN, all patients were followed 
up by case note review to assess outcome and to see if it had improved overall, but 
also to see if standardised management by specialist breast teams removed the 
variation associated with geography; treatment by specialist versus non-specialist 
surgeons; and socio-economic deprivation.
The aim of this chapter is to examine whether there is variation in survival associated 
with deprivation in patients who were entered onto the database between 1995 and 
1998; and secondly what factors if any are associated with differences in outcome.
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Methods 
Standards audited
The standards established by the Glasgow Managed clinical network were divided 
into diagnostic standards, surgical treatment standards, pathology standards and 
standards in adjuvant therapy.
Diagnosis
All patients should be treated by specialist breast surgeons in the context of a 
specialist breast clinic 
Surgical Management
Patients should have adequate clearance of their tumour 
All patients should have M l axillary staging 
Pathology
Tumour size, type and grade should be assessed 
All resected nodes should be examined for metastasis
Oestrogen receptor status should be measured using immunohistochemistry, with 
greater than 10% positive staining as a cut off for ER positivity 
Adjuvant therapy
All node positive women should be considered for chemotherapy 
(cyclophosphamide, methotrexate and fluorouracil (CMF) or anthracyline based in 
the context of a clinical trial in this time period)
High risk, node negative tumours should also be considered for chemotherapy (i.e. 
ER negative tumours that were high grade or had lymphovascular invasion) 
Radiotherapy should be given to all women having conservation surgery and to those 
high risk patients who had a mastectomy (large, node positive tumours)
All ER positive patients should be offered hormonal therapy (tamoxifen for the 
majority of patients)
Data on the above standards were collected prospectively on women with primary 
operable, breast cancer between October 1995 and December 2001. Women were 
treated at 5 different Glasgow hospitals (Glasgow Royal Infirmary, Western 
Infirraai'y Glasgow, Victoria Infirmary Glasgow, Southern General Hospital, Stobhill 
Hospital). Each is staffed by specialist surgical teams and treatment is determined in
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the context of a multidisciplinary team meeting. The compliance of the audit was 
assessed at intervals to check the standards were being maintained.
Data Collection
The period studied for this study was 1995-1998. During the study period, 1988 
patients were diagnosed with primary operable breast cancer and received surgical 
resection of their disease. Surgical management was divided into “conservation 
surgery,” (lumpectomy with axillary staging) and “mastectomy” (mastectomy with 
axillary staging) or limited resection (lumpectomy or mastectomy only).
Details of tumour pathology were collected, including histological grade, size, 
axillary node status and oestrogen receptor status. ER status was determined using 
immunohistochemistry, with greater than 10% staining considered positive. Tumour 
size, grade and lymph node status were combined and expressed as the Nottingham 
prognostic index. Nottingham prognostic index was then divided into good 
prognosis (NPI < 3.4), intermediate prognosis (NPI 3.41 -  5.4), and poor prognosis 
(N PI>5.4)
Patient demographics collected were; age and deprivation category and year of 
diagnosis. Deprivation was determined using the method of Carstairs and Morris 
(14). Postcode sectors are analysed for the prevalence of various census variables 
associated with socio-economic status, these are: ownership of a car, proportion of 
people in social classes IV and V, overcrowding and male unemployment. Postcode 
sectors are then scored and categorised into seven deprivation categories. For the 
purposes of this study, categories 1 and 2 were combined to “affluent”; 3, 4 and 5 
were combined to “intermediate”; and 6 and 7 were combined to “deprived”.
Follow up
Patients were all followed up at 5 years. Initially a search of the death registry was 
made for patients who were deceased since diagnosis. An additional search was 
made for cause of death. The case notes were then reviewed for all patients over the 
course of a year. Those patients who had not been reviewed in the breast clinic post­
op eratively or case notes were not available, were followed up by contacting their 
GP to check whether they were still alive.
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Statistical analysis
Statistical analysis was performed using SPSS for Windows version 9 (SPSS, 
Chicago, IL). Age, tumour size, histological grade, nodal status, oestrogen receptor 
(ER) status, year of surgery, surgical management and method of diagnosis and were 
individually examined for their association with deprivation category using tests of 
association.
Kaplan Meier technique was used to give a crude measure of overall suiwival from 
time of diagnosis to time of death and the relationship between deprivation and 
survival was obtained using a Log Rank test. Univariate survival analysis was 
performed using a Cox regression model to identify if there was a relationship 
between deprivation and survival. A Cox regression model was also used to assess 
the relationship between age at diagnosis, tumour size, tumour grade, nodal status,
ER status, year of surgery, type of surgery and method of diagnosis. A multivariate 
Cox regression model was then constmcted to identify which factors were 
independent predictors of suiwival.
This was a retrospective audit using data previously collected so ethical permission 
was not required.
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Results
In total 1988 patients were treated for breast cancer in the study period. 243 patients 
were excluded who had DCIS and no invasive breast cancer. In addition, 10 patients 
who had no deprivation category recorded were excluded. Case notes could not be 
obtained for 13 patients and these patients were also excluded. This left 1717 
patients diagnosed between 1995 and 1998 with data available for analysis.
The majority of patients were over 50, with the largest proportion of patients (32%) 
in the age group 55-64. Most patients were in the intermediate deprivation category 
(47.6%) with 18% of patients in the most affluent group and 34.4 % of patients in the 
least affluent group. There was a roughly even proportion of tumours treated in each 
year of the audit although there was a smaller number in the first year because the 
audit did not start until October 1995.
More patients had a mastectomy (58%) than had conservation surgery (40.1%), while 
only 1.9% had a resection but no treatment of their axilla. The majority of patients 
had symptomatic tumours (66.9%) while 32.0 % had screen detected cancers.
Most patients (63.2%) had small tumours (<2 cm), although 34.1 % had tumours 
between 2 and 5 cm, with only 2.5 % having tumours greater than 5 cm. The 
majority, 48%, had intermediate grade tumours, 22 % had low grade tumours and 
29.1% had high grade tumours. The majority of tumours were node negative 
(58.4%) and ER positive (73%).
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Table 3: Clinicopathological features of participants
Number of patients percentage
Age
<25 2 0.1
25-34 27 1.6
35-44 189 ILO
45-54 434 25.3
55-64 550 32.0
65-74 345 20.1
75+ 170 9.9
Deprivation category
Affluent 309 18.0
Intermediate 818 47.6
Least affluent 590 34.4
Year of surgery
1995 134 7.8
1996 531 30.9
1997 602 35.1
1998 450 26.2
Surgery
Conservation surgery 689 40.1
Mastectomy 995 58.0
Limited resection 33 1.9
Mode of presentation
Symptomatic 1149 66.9
Screen detected 548 32.0
Other 20 1.1
Tum our size
<2 cm 1086 63.2
2 cm - 5 cm 585 34.1
>5 cm 43 2.5
Unknown 3 0.2
Grade
I 388 22.6
II 824 48.0
III 500 29.1
Unknown 5 0.3
Lymph node status
Negative 1002 58.4
1-3 446 26.0
>4 232 13.5
Unknown 37 2.2
ER status
Positive 1254 73.0
Negative 421 24.6
Unknown 42 2.4
e.g. family history screening
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In general, deprivation was associated with worse tumour pathology (see table 4 
below). Deprived patients had significantly larger tumours than the affluent or 
intermediate group (%^ : p=0.003). There was no significant difference in tumour 
grade between the deprivation categories (%^ : p=0.224). However, there were 
significantly fewer node negative tumours in the least affluent group although this 
relationship was of borderline significance (%^ : p=0.045). When tumour factors were 
combined and expressed as the NPI, deprivation was strongly associated with worse 
NPI (p <0.001). There was no significant relationship between deprivation and ER 
status ((x :^ p = 0.744).
Deprived patients were more likely to have a mastectomy than the affluent or 
Intel-mediate groups (63.1% vs. 57.9 and 54.3 % respectively) {j^\ p=0.002). 
Intermediate deprivation patients were most likely to be diagnosed at breast 
screening compared with affluent and deprived patients (37.5% vs. 26.5 % and 
28.1% respectively (p <0.001).
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Table 4; Association of deprivation with pathology and treatment
Variable Affluent (%) 
N=309 (18.0)
Interm ediate (%) 
N=818 (47.6)
Deprived(%) 
N=590 (34.4)
P
Tum our size
<2 cm 
2-5 cm 
>5 cm
209 (67.6) 
95 (30.7) 
5(1.6)
541 (66.2) 
257 (31.5) 
19 (2.3)
336 (57.1) 
233 (39.6) 
19(3.2)
15.80 0.003*
Grade
I
II
III
Not Known
78 (25.2) 
136 (44.0) 
93 (30.1) 
2(0.6)
178 (21.8) 
416(50.9) 
222 (27.1) 
2 (0.2)
132 (22.4) 
272 (46.1) 
185 (31.4) 
7
8.201 0.224
Nodal status 
0
1-3
>4
Not known
188 (63.1) 
71 (23.8) 
39(13.1) 
11
495 (61.6) 
211 (26.3) 
97(12.1) 
15
319(55.1) 
164 (23.3) 
96(16.6) 
11
9.754 0.045*
NPI
Good
Intermediate
Poor
134 (45.1) 
117(39.4) 
48(15.5)
337 (42.1) 
357 (44.6) 
106(13.3)
203 (35.1) 
273 (47.2) 
106 (17.7)
13.230 0.01*
ER status
Positive 
Negative 
Not known
224 (76.5) 
69 (23.5) 
16
595 (74.2) 
207 (25.8) 
16
435 (75.0) 
145 (25.0) 
10
0.592 0.744
Surgical
management
Conservation 
surgei*y 
Mastectomy 
Limited resection
119(38.5)
179 (57.9) 
11
361 (44.1)
444 (54.3) 
13
209 (35.4)
372 (63.1) 
9
16.54 0.002*
M ethod of 
diagnosis
Symptomatic 
Screen detected 
Other
225 (73.5) 
81 (26.5)
3
504 (62.5) 
303 (37.5) 
11
420 (71.9) 
164 (28.1) 
6
19.667 0.001*
‘significant
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Case notes were reviewed of all 1717 patients studied at a median time of 6.02 years 
following diagnosis. Most patients (1574) were followed up for over 5 years 
however, 143 were followed up for less than 5 years at the hospital of diagnosis. 
Search of the death registry revealed that none of these 143 patients were deceased. 
Therefore, in total 1283 (75.9%) patients were still alive at follow up. 434 patients 
were deceased.
At 5 year follow up of those that had 5 year follow up available, 308 patients were 
deceased. Overall, 5 year survival was 80.4%.
At 5 year follow up there was a trend for worse survival in the most deprived group 
compared with the most affluent and intermediate groups (77.8% vs. 82.4 % and 
83.9% respectively). However on log rank testing this difference was not significant 
(p = 0.20) (see table 5 and graph 11).
Table 5: Cumulative survival by deprivation category
1 year 2 year 3 year 4 year 5 year
Affluent 0.983 0.935 0.893 0.847 0.824
Intermediate 0.980 0.951 0.919 0.873 0.839
Deprived 0.973 0.915 0.866 0.833 0.778
Log rank: p = 0.20
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Fig 11 ; Kaplan Meier curve of deprivation vs. survival
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On Cox regression analysis deprivation did not predict sum val (p = 0.19). Overall, 
age was a significant predictor of survival (p<0.001) with the worst survival in the in 
the youngest and oldest age groups and the best survival in the 45-54 age group (HR 
0.38; 95% confidence interval 0.28-0.51; p<0.001).The difference in survival 
between the two youngest age group and the 65-74 age group was not significant. 
NPI was also significantly associated with survival (p<0.001) with significantly 
worse survival in the high NPI group compared with the low NPI group (HR 6.11: 
95% confidence interval 4.64 -  8.04). ER status predicted survival (p<0.001), with 
ER negative having worse survival than ER positive tumours (HR 1.59: 95% 
confidence interval 1.29 -  1.94). Type of surgery also predicted survival (p < 0.001) 
with patients who had a mastectomy having worse survival (HR 1.85: 95 % 
confidence interval 1.51 -  2.27). If a patient had a symptomatic tumour they had 
worse suiwival than those diagnosed at breast screening (p<0.001; HR 2.22: 95% 
confidence interval 1.73-2.83). Year of surgery was not significantly associated with 
survival (p = 0.63).
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Table 6: Univariate Cox regression survival analysis
HR 95% confidence interval P
Deprivation Category 
Affluent 
Intermediate 
Deprived
1
0.90
1.09
0.69-1 .18
0.86-1 .43
0.19
Age
All age groups
<25
25-34
35-44
45-54
55-64
65-74
75+
1.96
1.36
0.60
0.38
0.51
1
1.42
0 .27-14 .0  
0 .73-2 .51 
0 .42-0 .85  
0 .28-0 .51 
0.36 — 0.66
1.07-1.87
<0.001
0.50
0.33
0.004
<0.001
<0.001
0.012
NPI
Good
Intermediate
Poor
1
2.15
6.11
1.65-2.78 
4.64 -  8.04
<0.001
Oestrogen receptor status
Positive
Negative
1
1.59 1.29-1.94
<0.001
Type of surgery
Consei-vation
Mastectomy
1
1.85 1.51-2 .27
<0.001
Year of surgery 1.02 0 .92-1 .14 0.63
How diagnosed
Screening
Symptomatic
1
2.22 1.73-2.83
<0.001
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After adjusting for NPI, ER status and age group; deprivation, type of surgery and 
mode of presentation were not significant predictors of outcome. Age remained a 
significant independent predictor of suiwival (p<0.001) with the worst suiwival in the 
under 25age group. NPI was also a significant independent predictor of survival 
(p<0.001). Compared with the good prognosis group the poor prognosis group had a 
hazard ratio of death of 4.82 (95% confidence interval 3.53 -6 .58). ER status was 
also a significant independent predictor of suiwival (p=0.005), with ER negative 
tumours having a significantly worse prognosis (HR 1.38: 95% confidence interval 
1.10-1.73).
Natasha C Henley, 2006
Chapter 1
65
Table 7: Multivariate Cox regression survival analysis
HR 95% confidence interval P
Deprivation Category 
Affluent 
Intennediate 
Deprived
1
0.93
0.67
0 .70-1 .24
0 .72-1 .29
0.866
Age
All age groups
<25
25-34
35-44
45-54
55-64
65-74
75+
2.05
1.05 
0.48 
0.40 
0.65 
1
1.26
0.28-14 .87  
0 .5 6 - 1.96 
0 .33 -0 .69  
0 .29-0 .55  
0 .48-0 .88
0.93-1 .71
<0.001
0.48
0.89
<0.001
<0.001
0.005
0.14
NPI
Good
Intermediate
Poor
1
1.67
4.82
1.26-2.21
3.53-6 .58
<0.001
Oestrogen receptor status
Positive
Negative
1
1.38 1.10-1.73
0.005
Type of surgery
Conservation
Mastectomy
1
1.27 0 .99-1 .62
0.06
Year of surgery 0.95 0 .85-1 .07 0.41
How diagnosed
Screening
Symptomatic
1
1.18 0 .8 7 -1 .6
0.29
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Discussion
This data shows that women from deprived areas presented with more advanced 
disease. They had larger tumours which were more likely to be node positive. In 
addition, they were more likely to have a mastectomy, and were less likely to be 
diagnosed at breast screening. However, despite worse pathology in the lowest 
deprivation category, deprivation did not predict survival. Significant predictors of 
suiwival were age, NPI, and ER status.
Clinicopathological features of the study population
The population studied were fairly typical. The majority were aged 45 to 64 (58.3%) 
which was partly a reflection of the inclusion of patients diagnosed at breast 
screening but also the demographics of the disease (124). The majority of patients in 
the study were from the intermediate deprivation category, with relatively few in the 
most affluent category. This is a reflection of levels of deprivation in Glasgow, 
which has some of the highest levels of deprivation in Britain (11).
The rate of mastectomy in the study group was surprisingly high, with just under 
60% of patients undergoing mastectomy. This was despite over 60% of them having 
tumours less than 2 cm and over 97% of them having tumours under 5 cm. The 
guidelines suggest that women with tumours under 5 cm should be considered for 
wide local excision unless they have a contraindication. It has been estimated that 
10% of tumours smaller than 2cm (T l) and 30% of tumours between 2cm and 5cm 
(T2) require a mastectomy due to a medical contraindication (68). In the current 
study 46.3% of patients with T l tumours and 77.9% with T2 tumours underwent 
mastectomy. The reasons for this high mastectomy rate and its relationship to 
deprivation are explored further in chapter two.
The majority of patients had symptomatic cancers (66.9%). However in the 
screening age group (aged 50-64) the majority of caneers were screen detected 
(60.1% screen detected vs. 38.9% symptomatic). The majority of cancers were of 
intermediate histological grade (48%) and were node negative (58.4%). In
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comparison with data available from the NHSBSP(125), the proportions of patients 
with intermediate histological grade tumours were similar (48% in the study vs. 49% 
in the NHSBSP). There were more high grade tumours in the current study (29% vs 
18% in NHSBSP) but this would be expected because the tumours in this study were 
both symptomatie and screen detected. Compared with the NHSBSP there were 
more node positive tumours in the current study (23% in NHSBSP compared with 
39%). Again, this is a reflection of the inclusion of symptomatic tumours in this 
study.
Deprivation and tumour pathology
This study has shown that deprived women presented with more advanced tumours 
than the more affluent patient groups. This finding is not a new one. Several studies 
have reported differences in tumour pathology between socio-economic groups. 
(5;9;10;40;41;45;49;126;127). However, the association between late stage at 
presentation and deprivation has not been consistent (10;41;44;45;78). Studies 
from the USA have also suggested differences in tumours stage at presentation in 
socially disadvantaged groups, however, social status in the USA is inextricably 
linked with race and it is difficult to extract from the data which is the more 
important factor (128-130). The earlier studies did not define clearly what stage 
actually meant (5; 126; 128-130), which made them less reliable, although more 
recent studies have clearly defined that stage means larger, node positive tumours 
(10;40;44;45). The current study has the advantage that it has data on tumour size, 
nodal status and tumour grade and it agrees with recent studies which have shown 
that socially disadvantaged groups present later with more advanced tumours.
There has also been a suggestion that women from deprived areas are more likely to 
present with biologically more aggressive disease, in terms of tumour grade (40;41) 
or oestrogen receptor status (10), although these results have not been consistently 
replicated. The current study has shown that there was no significant difference in 
tumour grade or oestrogen receptor status between deprivation categories. The study 
by Thomson et al (10) was carried out in the pre-breast screening era when there was 
less ER positive disease (65% in the affluent group and 48% in the deprived group 
compared with 76 vs. 75 in the current study). This may be due to the tendency for
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breast screening to identify slower growing ER positive tumours. In the cuiTent 
study there were more screen detected cancers in the affluent group so it would be 
expected that any differences in ER status would have been accentuated but this was 
not the case. The absence of a difference may be a reflection of changing patterns of 
risk factors for breast cancer, for example increasing use of hormone replacement 
therapy. This is discussed in more detail in chapter three.
Differences in histological grade between deprivation categories have been observed 
in two previous studies; however this study has not re-produced these results. Data 
on histological grade has not been routinely collected until relatively recently 
although the original grading by Bloom and Richardson was described in 1957
(131). In the study by Adams et al (40) deprivation was associated with less 
favourable histological grade but although they had more women in their study, 
grade was only available in 81.2% of patients at diagnosis. Equally, data on grade 
was only available in 82% of patients in the study by Taylor and Cheng (41), who 
also found an association with high grade and deprivation. The present study had 
histological grade available on over 99% of patients, which makes this data more 
reliable and suggests perhaps that the differences seen in the previously mentioned 
studies were a result of multiple comparisons rather than a genuine effect.
The reasons why people from deprived area should present with later stage tumours 
but not biologically more aggressive tumours are not clear. The larger size of the 
tumours may be related to a delay presentation to their GP. However, it has been 
previously reported that deprived patients with breast cancer are more likely to attend 
their GP practice (56). In addition, a meta-analysis looking at reasons for diagnostic 
delay in patients with breast cancer showed that low income was only a moderate 
predictor of diagnostic delay (55). The fact that the patients in the cun ent study were 
more likely to have node positive disease may also be due to a diagnostic delay. It 
may also be a reflection of more aggressive disease, although there was no 
significant difference in histological grade or ER status between deprivation 
categories.
Although differences in stage at presentation have been previously described prior to 
the introduction of breast screening, this study shows that these differences continue
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to exist. The introduction of breast screening should have helped to even out the 
differences in stage at presentation between socio-economic groups if all women 
attended, however, deprived women are less likely to attend breast screening. This 
has been shown in this study and agrees with findings in several other studies (32-35) 
and published data from the NHSBSP. Women from deprived areas in this study had 
larger, node positive tumours, rather than high grade, ER negative tumours which 
would suggest that these differences in tumour pathology are related to diagnostic 
delay or a symptomatic diagnosis rather than the development of more aggressive 
tumours.
The reasons why deprived women are less likely to attend breast screening are not 
obvious. Non-attendance at breast screening may be a reflection of difficulties in 
travelling to a breast screening unit, which are compounded by socio-economic 
deprivation. However, distance from a unit does not appear to affect attendance and 
screening uptake is greater in non-healthcare sites (35). So it appears that 
deprivation itself is more important than geographical location in determining 
attendance for screening mammography.
The current data have also shown that deprived women were more likely to have a 
mastectomy than more affluent women. This agrees with two previous studies 
(10;41). However, equally there have been studies which have suggested that there 
is no difference in surgical management between different socio-economic groups. 
This data has also shown that deprived women had larger tumours that tended to be 
node positive, so it is most likely that the ehoice of surgeiy was based on the tumour 
characteristics rather than unequal treatment for deprived and affluent women. This 
is discussed in greater detail in the following chapter.
Factors affecting survival 
Age
As expected, age was a significant predictor of survival from breast cancer (table?). 
The distribution of hazard ratio of death was compared with the 65-74 years old age 
group and showed the survival was worst in the youngest age groups and the oldest 
age groups. In the two youngest age groups (under 25 and 25-34) the confidence
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inteiwals are wide due to the small numbers of patients involved and therefore the 
difference in survival was not significant.
Nottingham Prognostic Index
NPI was a strong independent predictor of survival (table 7). The NPI has been 
extensively validated and is used routinely in the UK to determine adjuvant therapy 
as well as providing a basis for the assessment of newer tools to determine prognosis
(132). In the original description of the NPI, it was divided into 3 groups(42). It was 
subsequently subdivided into 5 and more recently 6 groups(132). In this study NPI 
has been divided into three prognostic groups (good, intermediate and poor) because 
this is the clinical use of the NPI in Glasgow to determine adjuvant therapy.
Oestrogen Receptor Status
Oestrogen receptor status was also an independent predictor of survival (table 7).
This agrees with previous studies. Although having an ER positive tumours itself 
does not confer a survival advantage, it does determine the response to hormonal 
manipulation which by extension improves survival (133).
The relationship between deprivation and survival
There were no suiwival differences between affluent and deprived women, despite 
the differences in tumour stage at presentation and mode of presentation. The 
univariate analysis of differences in five year survival approached significance but 
lost its significance on multivariate analysis.
The presence of a survival difference between socio-economic groups has been 
reported extensively. Initially, it was thought to be due to a paucity of data and 
inadequacies of data collection. However, with recent improvements in data 
collection at both regional and national levels, these deficiencies should have been 
reduced.
The reason why the current study has not demonstrated a survival gap is not clear. It 
may be due to a problem with small sample size. Previous studies have quantified 
the “deprivation gap” as between 6 and 7% difference in relative survival. However,
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these studies involved substantially larger numbers of patients (5;6;9;19). Studies 
with comparatively similar numbers to the present study found a more modest 
suiwival gap and in some this was accounted for by differences in stage at 
diagnosis(8;89; 134-136). Of the studies with similar numbers of patients there were 
further differences which might account for why they found a deprivation gap. Aziz 
et al found a significant difference in a small study of 286 patients in Pakistan. 
However, there is a greater difference in socioeconomic status between the most and 
the least affluent groups in Pakistan and healthcare is privately funded there (137). A 
study of 3920 patients in Switzerland identified a survival difference but again the 
Swiss healthcare system is privately funded so this might accentuate any differences 
(138). A further study from Australia which identified a deprivation gap based its 
measurement of deprivation on the location of the hospital of treatment (139). This 
provides a relatively crude measure of deprivation because it bases the comparison 
on large geographical units rather than small postcode sectors as in the current study. 
A recent study of 4645 patients in Sweden also identified a survival difference 
between rich and poor, measuring socioeconomic status by occupation or household 
income (140). However, in this study complete pathological data was not available 
for over a third of patients and had this been available, an association between 
socioeconomic status and survival might not have been found.
Thus there are several methodological reasons why other studies have demonstrated 
a difference and the current study has not. In agreement with this study, however, 
several others have found no difference in survival between affluent and deprived 
patients. A recent study of 3239 patients in the South East of England at 13 year 
follow up found that there was no survival difference (135). While a study of over 
15,000 patients diagnosed between 1977 and 1997 in Sweden showed that there was 
a survival difference but this was accounted for by later stage at presentation and 
death from intercurrent disease (134). This agreed with the findings of two Scottish 
studies which found a sum val difference but this was accounted for by differences in 
stage of disease at presentation (8;89).
The other reason that no survival difference has been demonstrated in this study may 
be due to length of follow up and inadequate numbers of patients. The median 
follow up was just over six years but this may not have been adequate to demonstrate
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a survival difference between the most and least affluent groups. At 5 years the 
estimate relative survival for women in England and Wales is 80%. However, after 
this survival continues to fall with 20 year survival estimated at 64 % for women 
diagnosed between 2001 and 2003 (data from Cancer research UK website:
W W W .info.cancenesearcliuk.org) . Therefore, although no survival difference was 
noted in this study it may be that there were not enough events to show an 
association between deprivation and survival. By the same token the number of 
patients in the study may not have been sufficient to show a survival difference. A 
recent Swedish study which examined a similar population of patients after the 
establishment of breast screening but with larger numbers of patients demonstrated a 
difference between the higher and the lower socio-economic groups(141). However, 
they only divided socioeconomic status into two groups which would have given a 
more homogenous group of patients and makes the results less reliable.
While the size of the study population and lack of long term follow up may have 
been the reason that no survival difference was seen in this group of patients, there 
may be other reasons for this. There may have been a genuine improvement in 
survival for the most deprived groups due to diagnostic or treatment factors.
Previously it has shown that differences in pathology between women of different 
socioeconomic groups might account for the deprivation gap. Evidence for this has 
been inconsistent and inconclusive. Two studies that noted a deprivation gap found 
that differences in stage at diagnosis only accounted for part of the difference (5; 9), 
while a the study by Thomson et al found no difference in stage at presentation but 
found a difference in ER status which seemed to only account for 10 % of the 
deprivation gap (10). On the other hand, two Scottish studies showed that stage at 
diagnosis did account for survival differences (8;89). In fact, the current study has 
shown that pathology is significantly worse in deprived group but it did not appear to 
influence survival. This would tend to suggest that improvements in diagnosis of 
breast cancer are unlikely to be responsible for the narrowing of the deprivation gap. 
Deprived women were also less likely to be diagnosed at breast screening. Although 
diagnosis at breast screening predieted survival on univariate analysis, after 
correcting for age and tumour stage this relationship was no longer significant. 
Therefore, it seems unlikely that improvements in attendance at breast screening over
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time have accounted for the improvements in survival in the most deprived patient 
group.
An alternative explanation is that there has been an improvement in breast cancer 
treatment that has narrowed the deprivation gap. The finding of this study that 
despite worse pathology deprived women did no worse than affluent women suggests 
that there may have been an improvement in the care specifically given to deprived 
women. Since the start of the breast cancer audit in Glasgow there has been a 
concerted effort to standardise treatment for patients. Eveiy patient is treated by a 
specialist breast surgeon in a specialist breast unit. Following diagnosis each patient 
is discussed at the Multi-disciplinary team meeting which comprises the surgeon, 
oncologist, pathologist and radiologist as well as the breast care nurses. At the initial 
meeting treatment is discussed and planned. The patient is again discussed post 
operatively to assess what adjuvant therapy is needed. In this manner, any 
geographical variation is excluded as well as any disadvantage from not being treated 
by a specialist breast team.
Both treatment by a specialist surgeon (91;92;121;142) and geographical variation 
(48;90;143) have been shown to affect outcome . Being treated by a specialist 
surgeon with a large case load improves outcome partly because of access to 
chemotherapy and radiotherapy services via multidisciplinary team working but also 
due to better axillary staging and locoregional control (91;92;121;142). The fact 
that breast cancer surgery in Greater Glasgow has been centralised to specialist units 
may have eliminated the variability amongst surgeons and thus improved outcome 
not only for all patients but especially for more deprived groups and narrowed the 
deprivation gap.
It has been shown that geographical differences are partly due to the specialist 
surgeon working within the locale. However , even correcting for the caseload of the 
surgeon, deprivation and other clinical factors, geographical location still remains a 
significant predictor of survival (8;90; 143). The explanation for this is not clear 
however, it seems likely that it is due to differences in the availability of adjuvant 
systemic treatment. Geographical differences in treatment that have previously been 
described were at health board level in Scotland (8;90) and at Health Authority level
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in England (48; 143). The Greater Glasgow area may actually be too small to 
display any significant geographical variation so this may have only had a limited 
effect on changes to adjuvant treatment offered to patient in different parts of the city 
and thus may not have been responsible for the observed improvements in outcome 
for the most disadvantaged group.
Changes in adjuvant therapy may also have had a role in the improvement in survival 
for the most deprived patients. The data shown here have shown that women from 
the most deprived group were more likely to have larger node positive breast 
tumours so they may have been more likely to have had chemotherapy. 
Unfortunately, data on the use of adjuvant therapy was not available for this cohort 
of patients. Several studies have shown the superiority of anthracyline based 
chemotherapy regimes over the CMF chemotherapy regime which was previously in 
routine use. The recent Oxford overview showed the survival advantage to be 4% 
with anthracylines over CMF (133). Anthracyline based chemotherapy has become 
part of routine adjuvant treatment in Greater Glasgow since the mid to late 90’s and 
prior to this it was only available in the context of clinical trials. It may, therefore, 
have had some effect on the improvement in survival in the deprived patients but this 
effect is likely to be small and difficult to quantify without data on adjuvant therapy.
Host factors may also have played in role in the reasons why deprived patients with 
breast cancer are doing better and nothing to do with the way breast cancer is 
diagnosed or treated. In fact, a study by MacLeod et al which was done prior to the 
setting up of the Breast Cancer Audit showed that there was no difference in the 
surgical and oncological care that patients received regardless of socio-economic 
status(56). In addition, although recent evidence has shown that as the gap in wealth 
between rich and poor has grown and so has the gap in life expectancy, on closer 
examination the difference in life expectancy has remained stable in women while 
getting wider in men (11). This is borne out by a recent study which looked at the 
differences in breast cancer mortality between affluent and deprived women which 
showed the gap to be static (19). The absence of a survival difference in the present 
study may be due to deprived women actually becoming healthier and therefore not 
dying from intercurrent disease.
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Conclusion
The previously described differences in survival between women from affluent areas 
and women from more deprived areas have not been demonstrated in this study. 
Although, women from deprived areas had larger tumours and were more likely to 
have node positive disease, this had no apparent effect on survival. Deprived women 
were less likely to attend breast screening and were more likely to have a 
mastectomy, however this also had no effect on survival.
While the absence of a survival difference may be due to insufficient numbers in this 
study or inadequate length of follow up, it may be due to improvements in the 
diagnosis and particularly treatment of breast cancer. Breast cancer services in 
Glasgow are delivered in the context of a multidisciplinary team which may have 
helped to even out geographical variation and variation between surgeons. 
Alternatively the survival improvements in the most deprived group may be a 
reflection of overall improvements in health.
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Does deprivation affect breast cancer management? 
Introduction
The findings of the previous chapter have suggested that the previously observed 
deprivation gap (10; 19) no longer exists in Glasgow. However, several other factors 
were shown to be different between affluent and deprived women. Deprived women 
appeared to have more advanced tumours at presentation, they were less likely to 
attend breast screening and they were more likely to have a mastectomy. The 
increased mastectomy rate in deprived patients may be a reflection of more advanced 
tumours in this group of patients, but it to what extent is it a reflection of different 
treatment in secondary care.
Trials have shown no long term survival advantage from mastectomy over breast 
conservation surgery for tumours up to 5 cm (62;63;144). Despite this mastectomy 
rates remain higher than expected (71). There does appear to be a higher rate of local 
recurrence in the patients who have conservation surgery and this is particularly seen 
with long term follow up and particularly in young women (145). This does not, 
however, affect survival. The reasons for the low uptake of mastectomy are not 
immediately obvious.
The relative contraindications to conservation are well documented: multifocal 
tumours; or 2"  ^trimester of pregnancy; history of previous irradiation to the 
affected breast; or a large tumour in a small breast that would result in an 
unacceptable cosmetic result. However, it is estimated that only a small proportion 
of all breast cancers will require a mastectomy for a medical reason(146). 
Unnecessary mastectomy can be associated with excess psychological co-morbidity 
(83) , particularly if the patient does not perceive that she had a choice in the decision 
for surgical treatment (84).
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The disparity in mastectomy rate between affluent and deprived women is well 
documented in studies from the USA, where healthcare is privately funded 
(38;72;75-77). However, these differences are not so well demonstrated in UK 
populations where healthcare is publicly funded (10;41). Glasgow is known to have 
high levels of deprivation (11) and had anecdotally been noted to have a high 
mastectomy rate. The aim of this chapter is to measure the mastectomy rate in 
Glasgow. If the mastectomy rate is higher than expected this might be a reflection of 
high levels of deprivation. In addition, to what extent were surgeons were 
influencing women in their choice of surgical management?
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Methods
Using data from the Greater Glasgow Breast Cancer Audit database (see previous 
chapter for description of data collection methods), patients who were diagnosed 
between 1996 and 2001 were analysed. Patients were treated in one of five hospitals 
in Glasgow (Glasgow Royal Infirmary, Western infirmary Glasgow, Stobhill 
Hospital, Southern general Hospital and Victoria Infirmary Glasgow). Each hospital 
has a specialist breast unit staffed by a multidisciplinary team.
Only patients with primary operable breast cancer were included. Those with 
tumours greater than 5 cm (on pathological reporting) and those with locally 
advanced disease unsuitable for mastectomy were excluded from the analysis. Data 
on tumour pathology (size, grade, nodal status and ER status) was recorded. Surgical 
management was divided into “conservation surgery,” (lumpectomy with axillary 
staging) and “mastectomy” (mastectomy with axillary staging). Patient’s age and 
deprivation category were also recorded. Deprivation was determined using the 
method of Carstairs and Moms (14). Categories 1 and 2 were combined to 
“affluent”; 3, 4 and 5 were combined to “intermediate”; and 6 and 7 were combined 
to “deprived”.
All data was entered onto SPSS for Windows version 9 (SPSS, Chicago, IL). 
Univariate analysis was performed using tests of association. Age, deprivation, 
tumour size, nodal status, histological grade, oestrogen receptor (ER) status and 
hospital were individually examined for their association with surgical management. 
Univariate analysis using x^  tests of association was also performed to identify which 
factors were significantly related to deprivation. Those factors that were 
significantly related to surgical management on univariate analysis were then entered 
into the multivariate model and subjected to stepwise logistic regression analysis to 
identify those factors which were independent predictors of surgery.
No ethical permission was required because this was an analysis of a retrospective 
cohort of patients.
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Results
Of the 3570 patients entered onto the database 3419 had tumours smaller than 5cm. 
The characteristics of the study population are shown in table 7 below. Of the 
patients with tumours<5 cm, 1588 (46.4%) underwent conservation surgery and 1831 
(53.6%) mastectomy. The majority were in the screening age group (50-64). The 
majority were of intennediate dep cat (48.5%). Most had tumours between 10 and 
19 mm (39.4) that were node negative (58.1%), grade II (44%) and ER positive 
(74,6%). 63.9% had symptomatic tumours and the majority were treated at hospitals 
1 and 4, (40.3% and 28.4%, respectively). There was an approximately even spread 
of patients over the years studied
Over the time period examined, the mastectomy rate decreased while the rate of 
conservation increased (fig 12).
On univariate analysis, deprived women were more likely to have a mastectomy 
(p<0.001). In addition, increasing tumour size was significantly predictive of having 
a mastectomy (p<0.001). Patients with positive nodes were also significantly more 
likely to have a mastectomy (p<0.001). High grade also predicted mastectomy 
(p<0.001) as did having a symptomatic cancer (p<0.001). The mastectomy rate also 
varied significantly between hospitals (p<0.001) (table 8).
Deprivation was significantly associated with having a larger tumour (p<0.001). 
Deprived women were less likely to be diagnosed at breast screening (p<0.001)
(table 9). There was no significant association between deprivation and nodal status 
(p=0.075), ER status (p=0.078) or grade (p=0.282) (table 9).
Step wise logistic regression modelling showed that deprivation maintained its 
significance when age and year of surgery, hospital of diagnosis were added into the 
model (0R=1.12; p=0.02) (table 10) but lost its significance when tumour size and 
was added to the model (OR=1,09; p=0.11). The multivariate analysis showed that 
age, year of surgery, tumour size, nodal status, histological grade, method of 
diagnosis, and hospital were independently predictive of surgical management (table 
11).
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Table 7: Characteristics of the study population
Characteristic Number %
Surgery
Conservation surgery 1588 46.4
Mastectomy 1831 53.6
Deprivation
Affluent 615 18.0
Intermediate 1657 48.5
Deprived 1147 33.5
Age group
<40 186 5.4
40-49 517 15.1
50-64 1704 49.8
65-74 667 19.575+ 345 10.1
Tumour size (mm)
<10 518 15.2
10-19 1348 39.4
20-29 944 27.6
30-39 441 12.9
40-49 168 4.9
Nodal Status
Negative 1986 58.1
Positive 1317 38.5
Missing 116 3.4
Oestrogen receptor status
Positive 2552 74.6
Negative 704 20.6
Missing 163 4.8
Grade
I 774 22.6
II 1515 44.3
III 1097 32.1
Missing 33 1.0
Method of diagnosis
Screen detected 1235 36.1
Symptomatic 2184 63.9
Hospital
1 1378 40.3
2 539 16.8
3 291 8.5
4 972 28.4
5 239 7.0
Year of surgery
1996 517 15.1
1997 582 17.0
1998 543 15.9
1999 582 17.0
2000 648 19.0
2001 547 16.0
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Fig 12; Percentage of patients having mastectomy or conservation for the years 
1996-2001.
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Table 8; Univariate analysis of factors determining surgical management
Variable ^Conservation (%) 
N=1588 (46.4)
^Mastectomy (%) 
N=1831 (53.6) P
Deprivation
Affluent
Intermediate
Deprived
285 (46.3) 
824 (49.7) 
479 (41.8)
330 (53.7) 
833 (50.3) 
668 (58.2)
17.301 <0.0001
Tum our size 
(mm)
<10
10-19
20-29
30-39
40-49
380 (73.4) 
770 (57.2) 
330 (35.0) 
90 (20.4) 
17(10.1)
138 (26.6)
577 (42.8) 
614(65.0) 
351 (79.6) 
151 (89.9)
472.492
<0.0001
Nodal Status
Negative 
Positive 
Not known
1117(56.2) 
390 (29.6) 
81
869 (43.8) 
927 (70.4) 
35
252.172 <0.0001
Method of 
diagnosis
Symptomatic 
Screen detected 
Not Known
409 (33.2) 
1396 (65.4) 
26
824 (66.8) 
737 (34.6) 
26
327.684 <0.001
Grade
I
II
III
Not Known
507 (65.5) 
667 (44.0) 
402 (36.6) 
12
267 (34.5)
848 (56.0) 
695 (63.4) 
21
158.889 <0.0001
Hospital
1
2
3
4
5
722 (52.4) 
198 (36.7) 
95 (32.6) 
472 (48.6) 
101 (42.3)
656 (47.6) 
341 (63.3) 
196 (67.4) 
500 (51.4) 
138 (57.7)
65.751 <0.0001
tfDefined as lumpectomy with axillary staging 
t  Defined as mastectomy with axillary staging
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characteristics.
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Variable Affluent (%) 
N=615 (18.0)
Intermediate (%) 
N=1657 (48.5)
Deprived (%) 
N=1147 (33.5)
P value
Tumour size
<10
10-19
20-29
30-39
40-49
101(16.4)
250(40.7)
160(26.0)
77(12.5)
27(4.4)
279(16.8)
673(40.6)
448(27.0)
191(11.5)
66(4.0)
138(12.0)
425(37.1)
336(29.3)
173(15.1)
75(6.5)
31.699 <0.0001
ER status
Positive 
Negative 
Not known
487(79.2)
112(18.2)
16
1262(76.2)
337(20.3)
58
846(73.8)
267(23.3)
34
8.405 =0.078
Nodal status
Negative 
Positive 
Not known
364(59.2)
224(36.4)
27
988(59.6)
619(37.4)
50
634(55.3)
474(41.3)
39
8.484 =0.075
Method of 
diagnosis
Screen detected 
Symptomatic
204(33.2)
411(66.8)
700(42.2)
957(57.8)
331(28.9)
816(71.1)
55.476 <0.0001
Grade
I
II
III
Not Known
140(22.8)
245(44.9)
191(31.2)
7
380(23.0)
755(45.6)
510(30.8)
10
254(22.1)
485(42.3)
396(34.5)
12
5.051 =0.282
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management.
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Relative risk of 
mastectomy (95% Cl)
P
Deprivation
Affluent
Intermediate
Deprived
1
0.89 (0.73-1.09) 
1.12 (0 .90 - 1.38)
0.02
Age <0.001
<40 1.39 (1 .02 - 1.90)
40-49 1.77(1.44-2.17)
50-64 1
65-74 2.47 (2 .04-2.48)
75+ 4.01 (3.06-5.25)
Year of surgery <0.001
1996 1.65 (1.29-2.14)
1997 1.32(1.03-1.68)
1998 1.66(1.29-2.13)
1999 1.32(1.04-1.69)
2000 1.04 (0.82-1.32
2001 1
Hospital
1
2
3
4
5
1
1.41 (1.02-1.95) 
0.84(0.63-1.13) 
1.89(1.30-2.74) 
1.06(0.78-1.44)
<0.001
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Table 11: Multivariate analysis of factors determining surgical management.
Variable Relative risk of Mastectomy ( 95% Cl) P
Deprivation =0.22
Affluent 1
Intermediate 0.95 (0 .76 - 1.19)
Deprived 1.12(0 .88- 1.43)
Age group
<40 1 <0.001
40-49 1.28 (0.78 -1.87)
50-64 1.39(0.98-2.00)
65-74 2.36(1.62-3.44)
75+ 4.60 (2.91-7.2)
Tumour size (mm) 
<10 1
<0.001
10-19 1.41 (1 .08 - 1.82)
20-29 2.55 (1.91 -3.40)
30-39 4.49(3.11 - 6.49)
40-49 13.47 (6.98-26.02)
Nodal Status
Negative 1 <0.001
Positive 1.90(1.60-2.26)
Oestrogen receptor =0.27
status
Positive 1
Negative 1.3 (0.91-1.42)
Grade <0.001
I 1
II 1 .54(1 .24- 1.90)
III 1.74(1.35-2.24)
Method of 
diagnosis <0.001
Screen detected 1
Symptomatic 2.13 (1 .72-2 .64)
Hospital
1 1 <0.001
2 1 .20 (0 .93 - 1.55)
3 1.32 (0 .9 5 - 1.85)
4 1.41 (1 .16-1 .73)
5 0.62 (0 .44-0 .87)
Year of surgery <0.001
1996 1.91 (1 .42-2 .57)
1997 1.42 (1 .0 7 - 1.89)
1998 1.76(1.32- 2.35)
1999 1.40 (1 .05 - 1.87)
2000 1.08 (0 .8 2 - 1.44)
2001 1
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Discussion
These data show that the mastectomy rate in Glasgow is higher than expected (68). 
On univariate analysis, deprived women were more likely to have a mastectomy than 
more affluent women, however they were also more likely to have larger 
symptomatic tumours which may explain why this association was not significant on 
multivariate analysis. Mastectomy rates were also found to be different between 
hospitals.
The mastectomy rate of just under 54% which has been demonstrated in this study, 
although higher than expected is probably appropriate. There is a wide variation in 
the rate of mastectomy (69;70) reported in the literature. The recent AT AC trial also 
looked at the variation in mastectomy rates internationally and showed that the rate 
of mastectomy in the UK as a whole is 42%, 12% less than the rate demonstrated 
here. In fact the AT AC trial (53) recruited patients from centres with active research 
programmes which would suggest that these patients were being offered state-of-the 
art treatment so in practice the mastectomy rate in the UK as a whole is probably 
higher than 42%. In addition, only women with ER positive tumours were included 
in the AT AC trial, these tend to be smaller than ER negative tumours. In the current 
study the mastectomy rate for ER positive women was 52% so the mastectomy rate 
in the AT AC trial may have been artificially low.
Based on figures from the United States, it has been estimated that 10% of tumours 
smaller than 2cm and 30% of tumours between 2cm and 5cm require a mastectomy 
due to a medical contraindication (68). In our study the percentages having a 
mastectomy were 38% and 72% respectively. This database does not identify which 
patients have a medical contraindication to conservation surgery but it is unlikely 
that a high incidence of medical contraindications would explain the relatively high 
mastectomy rate. It may be patient choice that is causing the high mastectomy rate. 
Several reasons have been suggested for why patients might choose mastectomy over 
conseiwation surgery. Access to radiotherapy sites has been suggested as a strong 
determining factor due to the time involved and the travelling and childcare costs 
incurred (80). Attendance for post-operative radiotherapy involves 5 to 6 weeks of
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therapy. In Glasgow, access to radiotherapy is equal for all patients, however, it may 
involve increased costs in terms of childcare which may influence some patients to 
avoid it by opting for mastectomy. There may also be a perception that local 
excision of the tumour does not constitute definitive treatment and this might 
influence the women to choose mastectomy instead. These attitudes are more 
prevalent in less educated women of lower socio-economic status (79). Alternatively 
it may be the attitude of the surgeons themselves to breast conservation surgeiy that 
influences the high mastectomy rate.
In the univariate analysis, this data has shown that women from deprived areas were 
more likely to have a mastectomy than women from more affluent areas. This may 
be a reflection of some of the above reasons why women choose mastectomy, for 
example, the inconvenience of radiotherapy, fear of local recuiTence or the surgeon’s 
recommendation. However, this data has also shown that women from deprived 
areas had larger and symptomatic tumours. On multivariate analysis of demographic 
factors alone, deprivation was an independent predictor of mastectomy, however 
when tumour size was added to the model it lost its significance. This suggests that 
the tumour size is the most important predictor of mastectomy and that the 
association seen between deprivation and mastectomy was a reflection of larger 
tumours rather than biased treatment.
Previous studies have been inconsistent in showing a difference in tumour size 
between affluent and deprived women. Several have shown no difference 
(10;41;45;78;120), while one study showed that deprived women presented with 
more advanced disease but no comment was made on tumour size (40). Part of the 
reason for this difference in tumour size might be explained by screening uptake. In 
the cunent study, deprived women were less likely to be diagnosed at breast 
screening and were more likely to present with symptomatic cancers. The uptake of 
breast screening in Glasgow is 68.1% (data from Scottish Breast Screening 
Programme) with the lowest uptake in the most deprived groups. This is not specific 
to Glasgow but has been noted previously (33). Alternatively the development of 
bigger tumours in deprived women could be a reflection of more aggressive disease. 
This data failed to show an association between deprivation and ER negative 
tumours, although they approached significance. Previous studies have in fact shown
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this to be the case (10) and perhaps had there been more patients included a similar 
result would have been demonstrated here. The reasons for the differences in tumour 
pathology have been discussed in the previous chapter and will not be repeated here.
Screen detected tumours tend to be smaller than symptomatic tumours however, 
being diagnosed at breast screening was predictive of conservation surgeiy 
independent of tumour size so this is probably reflective of screen detected tumours 
being impalpable. Deprived women were less likely to attend breast screening so 
this may also have contributed to their higher mastectomy rate in the univariate 
analysis.
It is interesting to note that pathological factors also determine surgical management. 
It is not surprising that patients with larger tumours are more likely to have a 
mastectomy, however, what is surprising is the number of patients with relatively 
small tumours (<2 cm) who had a mastectomy. It may well have been patient choice 
that detennined this but the database does not identify whether these patients had a 
contraindication to conservation surgeiy (for example multicentric disease). 
Interestingly, positive nodes were also associated with an increased likelihood of 
mastectomy, independent of tumour size. This finding agrees with that of Morrow et 
al (68). Palpable nodes on clinical examination is an indication for adjuvant therapy 
and not a contra indication to conservation surgery but the association of axillary 
node involvement with likelihood of mastectomy suggests that surgeons may feel 
that mastectomy is the more “aggressive” tieatment for advanced disease. 
Histological grade was also associated with increased likelihood of mastectomy on 
multivariate analysis. The reason for this is not entirely clear. Histological grade is 
not routinely assessed pre-operatively so should not affect surgical management.
The populations served by the different hospitals are similar in age and access to 
radiotherapy services although their levels of deprivation differ. Despite this, the 
variation in mastectomy rates between hospitals was quite marked. The rate was 
lowest in hospital 1 (47.6%) and highest in hospital 3 (67.4%). Part of this variation 
was due to the large breast screening practice in hospitals 1 and 4. However, in the 
multivariate model, which included method of diagnosis, hospital of treatment was 
independently predictive of surgical management. The relative risk of mastectomy
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varied from 0.62 in hospital 5 to 1.41 in hospital 4 when correcting for other 
pathological and demographic factors. All patients were treated in specialist units by 
a multidisciplinary team, however, it is the surgeons’ recommendations that are most 
important in determining treatment. Not all women will be offered a choice of 
surgery because they have a contraindication to mastectomy. Of those that do have a 
choice, some will choose mastectomy despite being suitable for conservation but 
these patients are in the minority and most will take the surgeons’ advice 
(73;79;147;148). The wide variety in mastectomy rates is therefore likely to be a 
reflection of individual surgeon’s practices and it is the individual surgeons who 
have an influence over choice of surgical management. Although guidelines have 
been produced recommending suitability for conservation surgery (67; 149), the wide 
variability suggests a lack of consensus.
Variation between surgeons has been previously described. It has been suggested 
that conservation rates are lower in older surgeons, and male surgeons (39; 148) 
although this finding has been inconsistent. It has also been suggested that non­
specialist surgeons and those working outside a teaching hospital are more likely to 
perform mastectomies(150). In addition, a high volume of patients also contributes 
to a lower mastectomy rate(39). Several of the units in Glasgow have more than one 
consultant surgeon working in them and the database does not identify each 
individual surgeon, so it is difficult to tell how much each of the above factors has 
influenced surgical decision making. All of the units are staffed by consultant 
surgeons with a declared specialist interest in breast surgery, so specialisation is 
unlikely to be a factor. Volume of patients is also unlikely to be important because 
hospital 5 had the smallest volume of patients but had the lowest relative risk of 
mastectomy. The demographics of the population served by each hospital are 
different but hospital was still an independent predictor of surgical management.
The fact that there were only 5 units included in this study makes it difficult to 
generalise about what features of each unit might influence the mastectomy rate. The 
most likely explanation is that the variation in mastectomy rate is down to the 
individual surgeons’ personal preference.
Variability in mastectomy rates and unnecessary mastectomy may result in excess 
psychological co-morbidity. In addition, if the unnecessaiy mastectomies are being
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performed in women from deprived background they will be doubly disadvantaged 
because they are more likely to have a worse outcome anyway from their poorer 
prognosis tumours. Initial work showed that similar rates of anxiety, depression and 
sexual problems were seen in patients who had mastectomy and conservation surgery 
(82). It was then thought that having a choice of surgery might be the important 
factor in detennining who developed psychological co-morbidity (151), but later still 
it was thought that it was the communication style of the surgeon that was the most 
important factor (84). A more recent prospective, randomised trial with longer term 
follow up suggested that in fact rates of psychological co-morbidity were lower in 
patients who had had conservation surgery (83). There is evidence that some 
psychological factors improve with time (152) and the reason that early studies did 
not show a difference may have been due to insufficient follow up that was too short 
to demonstrate any long-tenn co-morbidity.
A recent study in Glasgow showed that women from deprived areas were more likely 
to display psychological co-morbidity, in terms of greater anxiety, than more affluent 
women. Although deprived women have greater psychological co-morbidity 
unrelated to their cancer diagnosis, they also suffer psychological co-morbidity due 
to a lack of infoimation given to them by their hospital specialists and breast care 
nurses(87). This would suggest that deprived women might be more susceptible to 
psychological co-morbidity in two ways, the need for a mastectomy due to larger 
tumours, and also because they do not receive enough support post-operatively from 
the specialist breast team.
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Conclusion
The mastectomy rate in Glasgow is higher than that reported for the rest of the UK. 
Deprived women were found to have more mastectomies than affluent women. 
However, they also had larger, symptomatic tumours. The high mastectomy rate in 
deprived women was, therefore, a reflection of them having larger tumours rather 
than biased treatment of them and the high mastectomy rate was, in part, a reflection 
of high levels of deprivation in Glasgow. It does appear that women from deprived 
areas are being treated appropriately and the choice of surgery is based on tumour 
characteristics. There was a significant variation in the mastectomy rate between 
hospitals which suggests that there still remains a lack of consensus on the optimal 
surgical management of early stage breast cancer.
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Chapter 3
The changing pattern of oestrogen receptor positive breast 
cancer
Introduction
The pattern of incidence of breast cancer seems to be changing. In Scotland 
incidence has risen from 84.8/100,000 person-years at risk (European standard 
population) in 1980 to 118/100,000 person-years at risk in 2003. This increase has 
been essentially linear except for a period in 1990-1993 where there was a sharp 
increase due to the introduction if breast screening. Data from the West Midlands 
has suggested that the increase in incidence is different for different socio-economic 
groups, with an increasing incidence in affluent women and a relatively constant 
incidence in deprived women (see fig 6) (20). Despite the increasing incidence, 
mortality is falling. The mortality rate for Scotland in 1980 was 45.4/100,000 
compared with 41.1/100,000 in 2003. There has also been an improvement in 5-year 
survival, from around 60 % between 1977 and 1981 to around 80% between 1997- 
2001 (data from ISD Scotland). While part of the survival benefit might be 
attributed to breast screening or improvements in treatment, other factors may also 
play a role.
The answer may come from the changing pattern of honnone sensitivity in breast 
cancer. Two previous studies from the USA have shown an increasing incidence of 
ER positive breast cancer (153; 154). Even without systemic therapy oestrogen 
receptor (ER) positive breast cancer has a lower incidence of early recurrence 
compared to ER negative breast cancer(133). Additionally, ER positive cancers 
respond to endocrine manipulation, with agents such as tamoxifen, reducing the 
likelihood of recurrence and with the subsequent improvements in survival (133). 
Potentially, an increase in incidence of ER positive breast cancer compared with ER 
negative breast cancer might contribute to improvements in survival
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The risk factors for breast cancer are well documented, late age of first birth, 
nulliparity, early menarche, late menopause and use of HRT. All of these factors 
centre around exposure to oestrogen. More recently attempts have been made to 
identify if the risk factors for ER positive breast cancer and ER negative breast 
cancer are distinct and there is mounting evidence that this is the case. Increased 
risk of ER positive breast cancer is specifically associated with early menarche, 
nulliparity, delayed childbirth (155-159). In addition, HRT has been shown to not 
only increase the risk of breast cancer overall (27), but more so in ER positive 
tumours(160). Adult obesity is also known to be associated with an increased risk of 
ER positive breast cancer (161), while childhood obesity appears to be relatively 
protective (162).
The incidence of these risk factors for oestrogen receptor positive breast cancer 
appears to be increasing. Age at menopause has increased while age at menarche has 
decreased (25). More women are nulliparous or have an older age at first live birth 
(154). Use of honnone replacement therapy has increased (27), as have adult and 
childhood obesity (163). Moreover, there is a difference in the incidence of these 
risk factors between socio-economic groups. Women of higher socioeconomic status 
have a higher age at first birth with a higher incidence of nulliparity. They tend to 
have a shorter duration of breast feeding and have a later menopause (4). In addition, 
they are more likely to take HRT (28). This raises the question of whether changes 
in the biology of breast cancer (as determined by the ER status) could account for the 
changing pattern of incidence and the differences in outcome between affluent and 
deprived women.
Hormonal status of breast cancers can be determined using immunohistochemistry 
(IHC) or ligand binding assay (LBA). Until the 90’s LBA was the only method in 
routine clinical use, this was then superseded by IHC, which was quicker, required 
less tissue, and did not use radioactive isotopes. IHC is also more sensitive and 
specific than LBA, with a difference in sensitivity of around 10% (164; 165). Two 
previous studies based on data from the USA have suggested that although the 
incidence of breast cancer has increased, there has been a disproportionate increase 
in ER positive tumours(153;154). One reported a 6 % increase between 1973 to
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1977 (153) and the other a more modest increase of just over 2% between 1992-1998 
(154).
In this chapter, data on ER status obtained from women diagnosed between 1980 and 
1988 determined by LBA, before the introduction of breast screening, is analysed 
and compared with a group of women diagnosed in 1996 -2001, who had ER status 
detennined by IHC, after the introduction of breast screening. It was likely that the 
later group would have a greater proportion of honnone sensitive tumours due to the 
differences in technique; however, the hypothesis of this chapter is that this increase 
in the proportion of ER positive tumours would not be accounted for solely by 
differences in technique. In addition, if there had been an increase in the proportion 
of ER positive tumours, was it greater in affluent women compared with deprived 
women?
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Methods
The study compares two cohorts of patients who presented with primary operable 
invasive breast cancer. The first cohort was symptomatic and was diagnosed 
between 1981 -1988. The second cohort was both symptomatic and screen detected 
and was diagnosed between 1996-2001.
hr the early cohort, 2423 patients were diagnosed at 4 different hospitals and were 
entered into the analysis. This cohort represents all patients diagnosed at these 4 
hospitals during the time period examined, who had ER status determined by ligand 
binding assay (LBA). ER status was determined at the time of surgery in one 
laboratory by LBA on the cytosolic fraction, using standard techniques as described 
elsewhere (166). This laboratory was subject to External Quality Assessment 
(EQA). Tumours with an ER content of 20 fmol/mg protein were considered to be 
ER positive and likely to respond to endocrine therapy.
In the later cohort, 3115 patients were diagnosed at the same 4 hospitals and had ER 
status determined by IHC. These patients were from the Greater Glasgow Breast 
Cancer Audit database, which has been used in the preceding two chapters. Patients 
from hospital five were excluded as there were no patients for this hospital in the 
early cohort. IHC was performed on each patient using standard techniques (167) in 
2 different laboratories (at hospitals 1 and 4). 10% positive staining was taken as the 
lower limit of ER positivity. The IHC methods were identical in both laboratories 
and were subject to EQA.
Patient age was also recorded as well as method of diagnosis (screen detected or 
symptomatic) hospital of diagnosis, deprivation category. Deprivation was 
determined using the method of Carstairs and Morris(14). The seven dep cats were 
combined to “affluent” (1 and 2), “intennediate” (3, 4 and 5) and “deprived” (6 and 
7).
All data was entered onto SPSS for Windows version 9 (SPSS, Chicago, IL). 
Univariate statistical analysis was performed using tests of association. Age,
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deprivation, hospital of diagnosis and time period of diagnosis were individually 
examined to assess whether they were associated with having an ER positive tumour 
in each time period.
Those factors that were significantly associated with likelihood of having an ER 
positive tumour were entered into the multivariate model and analysis was perfoiTued 
using stepwise logistic regression analysis to identify which factors were 
significantly predictive of ER status.
Ethical permission was not sought because this was a retrospective analysis of two 
cohorts of women in whom data had aheady been collected.
Natasha C Henley, 2006
Chapter 3
Results
97
In the early cohort contained 2152 patients, o f  these 1078 (50.1%) had an ER 
positive tumour. In the later cohort 2471 (79.3%) o f  3115 patients had ER positive 
tumours. This difference was statistically significant (p<0.0001). There were 174 
patients diagnosed in the late time period who did not have data on ER status 
available and these patients were excluded
There was no significant change in percentage o f  ER positive tumours over the years 
o f  the early time period (%": p = 0.11) see fig 13. There was, however, significant 
variation in percentage o f  patients with an ER positive tumour between years in the 
late time period (x^:p<0.001)
100
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Fig 13: Percentage o f  ER positive tumours in each year o f  the early time period
Natasha C Henley, 2006
Chapter 3
98
(A0a
Xm r r ™
1996 1997 1998 1999
Year
2000 2001
Fig 14; Percentage o f ER positive tumours in each year o f the late time period 
Demographics o f  the 2 study groups
The demographics o f  the study groups differed significantly with respect to age 
p<0.0001), and deprivation category p<0.0001) (see table 12).
Table 12: Comparison o f  population demographics
Early Late
Age group <39 148 (6.9) 169 (5.1)
40-49 373 (17.3) 464(14 .9 )
50-64 856 (39.8) 1588 (51.0)
65-74 508 (23.6) 584 (18.7)
75+ 267(12 .4 ) 319(10 .3 )
P <0.0001*
Deprivation Category Affluent 432 (20.1 574(18 .4)
Intermediate 789 (36.7) 1550 (49.8)
Deprived 931 (43.3) 991 (31.8)
P<0.0001*
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The patients in the later cohort had significantly smaller tumours compared with the 
early cohort p<0.001). Patients in the later cohort were more likely to have node 
negative tumours than the early cohort (x^: p<0.001) (see table 13)
Table 13: Comparison of tumour characteristics in the two cohorts
Early cohort Late cohort
Tumour size <10 58 (4.7) 478 (15.3)
10-19 310(25.2) 1242 (39.9)
20-29 365 (29.7) 811 (26.0)
30-39 209(17.0) 352(11.3)
40-49 109 (8.9) 136(4.4)
50+ 179 (14.6) 96 (3.1)
Missing 724 0
P<0.001
Nodal status Negative 589 (34.8) 1814(60.1)
1-3 nodes 598 (35.3) 765 (25.4)
4 or more nodes 236 (29.9) 437 (14.5)
Missing 729 99
P<0.001
Univariate Analysis
o f Age
Increasing age was associated with an increased likelihood of having an ER positive 
tumour (p<0.0001). This association remained when considering each time period 
separately. The proportion of ER positive tumours increased in all age groups over 
time (table 14).
Effect o f deprivation
Deprivation was not associated with likelihood of having an ER positive tumour in 
either the early or the late cohort ( %^ : p = 0.170 and 0.187 respectively) (table 14).
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Variation between hospitals.
In the early cohort the variation in the proportion of ER positive tumours in each 
hospital was not significant on univariate analysis. In the later cohort there was 
significant variation in the proportion of ER positive tumours between hospitals (p = 
0.009) (table 14).
Multivariate analysis
On multivariate analysis, patients diagnosed in the later time period were more likely 
to be ER positive (RR 3.22 p<0.0001). This was independent of age, hospital or 
method of diagnosis or deprivation. Older age (p<0.001) and method of diagnosis 
(p<0.001) were independently associated with increased likelihood of having an ER 
positive tumour. Hospital of diagnosis and deprivation lost their association with 
ER positivity (table 15).
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Table 14: Univariate analysis of association between having an ER positive tumour 
and age at diagnosis, deprivation and method and hospital of diagnosis (p value 
derived from test)
Early -  No. ER 
positive (%)
Late -  No. ER 
positive (%)
Age <39 46(28.9) 102 (63.8)
40-49 162 (38.8) 336 (72.4)
50-64 471(49.6) 1296 (81.6)
65-74 337(56.4) 475 (81.3)
75+ 172(57.7) 262 (82.1)
P <0.000 <0.000M-
Deprivation 1 231 (53.5) 467 (81.4)
2 421 (48.5) 1235 (79.7)
3 464 (49.8) 769 (77.6)
P 0.252 0.18
How Diagnosed Symptomatic 1497 (75.6)
Screen detected 974 (85.7)
P <0.001
Hospital 1 192 (46.5) 405 (76.1)
2 403 (50.6) 1127 (82.0)
3 163 (50.8) 195 (76.8)
4 320 (51.5) 744 (77.9)
P 0.425 0.009^
'Statistically significant
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Table 15: Multivariate analysis of association between having an ER positive 
tumour and age at diagnosis, hospital of diagnosis, deprivation and method of 
diagnosis.
Relative risk of ER positive 
tumour (95% confidence 
interval)
P value
Year 1980-1989 1 <0.0001
1996-2001 3.22 (2.81 to 3.69)
Age <39 1 <0.0001
40-49 1.49 (1.14 to 1.97)
50-64 2.06 (1.39 to 2.67)
65-74 2.71(2.06 to 3.55)
75+ 2.97 (2.19 to 4.00)
Hospital 0.22
Deprivation 0.126
Method of diagnosis Symptomatic 1 <0.0001
Screen detected 1.81 (1.46 to 2.26)
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Discussion
This data shows that there has been an increase in the proportion of hormone 
sensitive breast cancer between the two time periods, from 50.1% to 79.3%. The 
increase in ER positive tumours occuiTed in all deprivation categories and there was 
a trend for more ER positive tumours in the most affluent group, however, this was 
not significant in either of the time periods. There was an increase in the proportion 
of ER positive tumours in all of the age groups, but the increase was particularly 
marked in those patients under 65. Screen detected tumours were more likely to be 
ER positive, and there was no significant association between hospital of diagnosis 
and ER status. The increase in percentage of ER positive tumours over time was 
independent of age, deprivation, breast screening or the hospital of diagnosis. Age 
was independently predictive of having an ER positive tumour regardless of how ER 
status was determined.
The rate of 79.3% ER positive tumours in 1996-2001 is similar to that of Li et al. 
(154), who found a rate of 75.4 in 1992 and 77.5 in 1998. However, in the early time 
period the proportion of ER positive tumours was only 50.1% which is significantly 
lower, Thomson et al demonstrated an ER positivity rate of 61.2% for patients 
diagnosed from 1980 onwards who had ER status determined by LB A. They used a 
similar cut of 20 fmol as determining ER positivity (168). Alberts et al found a rate 
of 57% ER positive tumours for node positive patients who had ER determined by 
LBA (169). While the rate demonstrated here of 50.1% in the early cohort is 
significantly lower than the later cohort it is largely similar to groups of patients 
diagnosed at a similar time. The reason for this dramatic increase in ER positive 
breast cancer may be methodological because two different types of assay were used 
in the study or there has genuinely been an increase in ER positive breast cancer.
The obvious shortcoming of this study is that two different types of assay were used. 
Concordance between the two techniques has variously been suggested to be around 
80-90% (164; 165). LBA tends to underestimate ER positivity, especially in those 
tumours that are weakly positive for ER by IHC (169). In addition, LBA tends to 
underestimate ER positivity in pre-menopausal women because IHC detects
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oestrogen bound receptors while LBA using short term incubation cannot (169). 
However, with the longer incubation time of 24 hours used in this LBA, endogenous 
oestrogen is displaced by the radioactive ligand so this effect should be minimal 
(166). Taking these factors into account we would expect the increase in proportion 
of ER positive tumours to be smaller than the 30.3% we observed. Thus, 
methodological differences do not explain all of the increase.
Although concordance between LBA and IHC has been suggested to be 80-90% 
(164). The discordance is minimised by using a cut off of 20 fmol/mg protein rather 
than 10 fmol/mgprotein (170), however, it is difficult to predict which of our results 
would be discordant. Comparison of these results with the results of previous studies 
might give some assessment of the expected magnitude of discordance that might be 
obseiwed if the tumours from the early time period were re-stained using IHC (table 
16). All of these studies measured ER status using LBA and IHC on the same 
tumours samples.
Table 16: The relative change in ER status seen in previous studies
Study Haivey et 
0/(171)
Alberts et o/(169) Thomson et al 
(168)
Stierer et 
0/(172)
% ER positive 
by LBA
78.9 57 61.2 76.2
% ER positive 
by IHC
70.5 55 70.2 81.2
% Absolute change in 
ER positive tumours
-8.4 -2 +9 +5
% Relative change in 
ER positive tumours
-40 -5 +23 +21
It is clear from these results that the effect of differences in methodology would not 
account for all of the increase in ER positive breast cancer we have observed. At 
worst it would account for a 23% increase in ER positive breast cancer in moving 
from LBA to IHC (168). We must therefore be seeing a genuine change in the 
prevalence of hormone sensitive breast cancer of at least 7 %, although it could be 
higher.
A further shortcoming of this study is the differences between the two populations. 
There were significantly more women in the age group 50-64 in the later cohort. In
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addition, there were more women in the intermediate and affluent women in the later 
cohort. There were also significant differences in the tumour pathology. There were 
more small, node negative tumours in the later cohort, although pathological data 
was not available for a significant proportion of the early cohort of patients. These 
differences are largely attributable to the introduction of breast screening in the 
intervening period. This meant that more patients were diagnosed with breast cancer 
in the 50-64 age group. In addition, deprived women are less likely to attend for 
breast screening (data from Scottish Breast Screening Unit), so deprived patients are 
relatively under represented. Furthermore, between the census of 1981 and 2001 the 
population of Scotland became more affluent (16). Patients diagnosed at breast 
screening are more likely to have smaller, node negative tumours because they 
should be picked up at an earlier stage. Despite these differences, the increase in ER 
positive tumours between the early and late cohorts was independent of age or 
deprivation, so these factors had a minimal effect.
Apart from the methodological difficulties there may well have been an overall 
increase in ER positive breast cancer. There has not, however, been a different rate 
of increase for each of the deprivation categories which might explain why affluent 
women have previously been observed to have a better outcome from breast cancer.
It has previously been shown that affluent women are more likely to have ER 
positive breast cancer (10). In agreement with this finding, this study has 
demonstrated a significantly greater proportion of ER positive breast cancer in the 
affluent group when considering both groups of patients together, but this was not 
true when each cohort of patients were considered separately. Therefore the increase 
in ER positive breast cancer which has been observed overall has occurred for all 
deprivation categories and any change in aetiological factors must be true for 
everyone and not just the more affluent patients.
Not only do ER positive and ER negative breast cancer behave differently in 
response to hormone manipulation (133), but recent studies have identified distinct 
patterns of relapse for ER positive and ER negative cancer, which has suggested that 
they are two different diseases (173). ER negative breast cancer tends to relapse 
early within the first two years of follow up and there is a difference in survival 
compared with ER positive breast cancer, however, with longer term follow up this
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difference appears to diminish (173). This has lead to the observation that the 
aetiologies of the two types of breast cancer are distinct (174).
It has long been established that older age is associated with an increased incidence 
of ER positive breast cancer(157). These results show that regardless of how ER 
status is measured this relationship remains. There was a significant change in the 
age distribution between the two cohorts of patients examined, which was due to the 
introduction of breast screening, and this may have confounded the results by giving 
a lead time bias. Breast screening is more likely to pick up the slower growing 
tumours, ER positive tumours and its introduction in between the two cohorts 
examined here may have increased the number of ER positive tumours that were 
diagnosed. However, there was a general increase in the proportion of ER positive 
tumours across all age groups, which suggests that while breast screening 
undoubtedly had an affect, other factors must also have been responsible.
ER positive breast cancer is associated with early menarche and nulliparity 
(175; 176), however, this appears to be more important in post-menopausal breast 
cancer than premenopausal breast cancer (156; 162). Patterns of fertility have 
changed over time, with more nulliparous women and most women having a later 
age at first pregnancy and women having an earlier menarche (4). Improvements in 
socio-economic status mean that women tend to have their first pregnancy later and 
tend to be nulliparous. In addition, childhood malnourishment is associated with 
later menarche and early menopause(177), so improvements in nutrition overall 
should result in earlier menarche. Changes in these reproductive factors may 
therefore have contributed to an increase in ER positive breast cancer, however, as 
they are all associated with socio-economic status one might expect to see a 
difference in incidence of ER positive breast cancer between the deprivation 
categories. This suggests that either these factors only make a small contribution to 
the likelihood of having an ER positive breast tumour or the difference in these 
reproductive factors between deprivation categories is small.
HRT use is associated with increased breast cancer risk (27). Its use has rapidly 
increased since its introduction in the 80’s (22). Studies have also shown that HRT 
use is particularly associated with ER positive breast cancer (178; 179). Therefore,
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increases in HRT use may also be responsible for the increase in ER positive breast 
cancer seen in this study. HRT use is also associated with affluence(28) and 
improvements in affluence overall might account for increases in HRT use and by 
extension ER positive breast cancer. The difference in proportion of ER positive 
breast cancer between the deprivation categories in this study was modest and may 
have been contributed to by differences in the use of HRT but it is more likely that 
there has been an overall increase in uptake.
The incidence of obesity has increased over time (180). The association of obesity 
and risk of ER positive breast cancer is somewhat complicated. In pre-menopausal 
breast cancer obesity appears to be protective for risk of ER positive breast cancer 
(162). Conversely, in postmenopausal women it appears to increase the risk (161). 
Increased levels of physical activity in younger and older women appears to reduce 
the risk of both ER positive and ER negative breast cancer (161). Post menopausal 
obesity is associated with higher levels of endogenous oestrogen and this is thought 
to be the reason why obesity is associated with increased postmenopausal cancer risk 
(161). In premenopausal women, obesity is associated with menstrual iiTegularities 
resulting in lower circulating oestrogen and lower breast cancer risk (162). It would 
therefore be expected that increasing obesity in the population as a whole would 
cause a rise in ER positive postmenopausal but not premenopausal breast cancer but 
these results have shown that ER positive breast cancer has increased for all age 
groups.
ER negative breast cancer has previously been shown to be associated with socio­
economic deprivation in Scotland (10). In addition, a study from California showed 
that the difference in incidence of ER positive breast cancer is independent of ethnic 
group or age (176). These results show that there is an excess of ER negative 
tumours in deprived patients when both cohorts were considered together, but this 
association did not remain on multivariate analysis or when each cohort was 
considered individually. The aetiological factors for hormone sensitive breast cancer 
discussed above tend to be more prevalent in affluent women. They tend to have an 
earlier age at menarche, are more likely to be nulliparous or have a later age at first 
birth and they are more likely to take HRT. The incidence of these factors has 
increased more in affluent women than deprived women so it would be expected that
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the increase in ER positive breast cancer would be more marked in affluent women 
but this was not the case. The reason this was not identified may be due to 
inadequate numbers. However, the results from chapter 1 have suggested that a 
survival gap no longer exists and the incidence of risk factors may have increased for 
the whole population.
Conclusion
There appears to have been a genuine increase in the proportion of ER positive breast 
cancer over time. Differences in the technique of determining ER status may 
account for some of the difference but they do not explain all of it. Changes in 
hormonal factors that have been implicated in the aetiology of ER positive breast 
cancer and the increasing use of HRT over the last 20-30 years may have led to more 
ER positive breast cancer. Although these aetiological factors are more prevalent in 
affluent women, the increase in ER positive breast cancer was seen in all deprivation 
categories and all age groups. This suggests that there have been global changes in 
aetiological factors which have increased the proportion of ER positive breast cancer 
but would not account for the increase in incidence in affluent groups.
The reasons for the increase in ER positive breast cancer are probably multifactoral. 
Increasing use of HRT has probably increased the incidence of postmenopausal 
breast cancer. In addition, the introduction of breast screening has resulted in the 
detection of more slow growing tumours which tend to be ER positive. Increases in 
premenopausal breast cancer are partly due to improvements in nutrition resulting in 
earlier menarche as well a general improvement in affluence for the whole 
population has led to the increasing incidence of nulliparity and later age of first 
birth.
Alternatively there may be an as yet unidentified endogenous biological change 
occurring within breast cancer cells themselves, which is resulting in the 
development of more ER positive breast cancer. Understanding the shifting pattern 
of hoiuaone sensitive of breast cancer is important for detennining adjuvant therapy 
for breast cancer.
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Chapter 4
Deprivation and the systemic inflammatory response to 
breast cancer.
Introduction
Thus far, pathological features of the tumour have been examined as potential 
reasons why deprived and affluent women should have different breast cancer 
outcomes. Traditionally, prognosis in breast cancer has been determined by 
pathological characteristics of the tumour and axillary nodes using the Nottingham 
prognostic index or TNM stage. In addition, the oestrogen and HER-2 receptor 
status of the tumour specimen are routinely measured to guide adjuvant therapy. The 
preceding chapters have shown that while some of these factors might explain the 
deprivation gap, they do not account for the differences that have previously been 
observed, which leaves the question of what other factors might be involved.
Pathological factors do not provide clear distinction between patients who will go on 
to develop recurrence and die of their disease. There is, therefore, continuing interest 
in evaluating factors which will improve the prediction of outcome. To date, serum 
markers of prognosis have had limited usefulness and have not been put into routine 
clinical use.
It is increasingly recognised that it is not only the intrinsic properties of tumour cells 
themselves which determine tumour spread, but also the host inflammatory response 
(181 ; 182). Indeed, the systemic inflammatory response, as evidenced by elevated 
circulating concentrations of C-reactive protein, has been shown to be a disease 
independent prognostic factor in a variety of operable tumours (183-187). In 
particular, an elevated C-reactive protein, measured either prior to or following 
curative surgery, has been shown to predict recurrence and overall survival, 
independent of stage, in patients with primary operable colorectal (96) pancreatic 
(183) and bladder cancer (185).
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There have only been a few studies which have examined the prognostic role of C- 
reactive protein concentration or its primary mediator interleukin-6 in breast cancer 
(102; 112; 114-116; 118; 188). These studies described a raised systemic inflammatory 
response in metastatic and locally advanced breast cancer. However, to date the 
relationship between C-reactive protein, 11-6 and outcome has not been examined in 
women with primary operable breast cancer.
A raised C-reactive protein is also known to exist in patients from more deprived 
socio-economic backgrounds. Part of this increase appears to be due to increased 
prevalence of smoking and increased BMI. However, there also appears to be a 
raised “inflammatory state” which exists in people of lower socio-economic status 
(94;95). People of lower socio-economic status have CRP levels that are within the 
reference range for the population but below that which is clinically significant, and 
this appears to predispose them to coronary heart disease and diabetes (189).
Whether a raised background CRP predisposes to poor outcome in cancer is not 
clear. A recent study in colo-rectal cancer showed that people of lower socio­
economic backgrounds had worse overall and cancer specific survival. In addition, it 
appeared in these patients that the presence of a systemic inflammatory response in 
the more deprived patients accounted for the differences in survival (96). In patients 
with primary breast cancer it has been shown that deprived women have a raised 
systemic inflammatory response which is independent of tumour pathology (120). 
This therefore poses the question of whether socio-economic differences in outcome 
from breast cancer might be attributable to a raised background inflammatory 
response. If there is a raised inflammatory response to cancer, is this due to a raised 
background response to other inflammatory co-morbidities or is it due to an 
excessive and inappropriate response to the primary tumour itself?
The first aim of this chapter is to examine if socioeconomic differences in 
inflammatoiy response to primary breast cancer exist pre or post operatively. 
Differences in pre-operative systemic inflammatory response would reflect the host 
response to the tumour itself and differences in the post-operative response would 
reflect background inflammation. The second aim is to assess whether the pre or
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post operative systemic inflammatory response predict survival and if they might 
account for socio-economic differences in outcome.
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Methods
Patients
Patients undergoing surgery for primary operable breast cancer in Glasgow Royal 
Infirmary and Western infirmary Glasgow were recmited for this study between 
October 2000 and January 2002. Each patient was approached pre-operatively, 
counselled about the study and asked to sign a consent form.
Each patient had a sample of venous blood taken in an EDTA tube. A second sample 
of blood was then obtained approximately 12 months later. All samples were 
centrifuged at 1000 x g for fifteen minutes then serum was stored at -20'^C for 
subsequent analysis
Demographic data were also collected for each patient, including age, smoking 
status, and deprivation category (measured using Carstairs scores). The pathological 
data was also recorded for each patient. Including tumour size (measured in 
millimetres), lymph node involvement and histological grade. These were combined 
and expressed as the Nottingham prognostic index, which was further categorised 
into good prognosis ( NPI < 3.4), intermediate prognosis (NPI >3.4 <5.4) and poor 
prognosis (NPI >5.4). The ER status and HER-2 status were also recorded. Those 
patients who had greater than 10% positive staining on IHC for oestrogen receptors 
were considered positive. The patients who were 3+ positive on IHC for HER2 were 
considered positive. Those patients who were 2+positive on IHC for HER2 had 
FISH testing. Those that amplified on FISH were also considered HER2 positive as 
well.
The nature of adjuvant treatment was recorded for each patient. Including whether 
they underwent radiotherapy or chemotherapy and if they had hormonal therapy, this 
was mainly in the form of tamoxifen.
All patients were then followed up until 3 1®‘ July 2005 for recurrence or death. 
Initially the death register was searched for those patients who were deceased and 
their cause of death. Case notes were reviewed for all patients to identify if there
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had been further deaths not recorded in the death registry. Those patients (of whom 
there were 4) whose case notes could not be obtained and who were not registered as 
deceased in the death register were assumed to be fit and well with no recurrence of 
their disease.
Biochemical Analysis 
C-reactive protein
C-reactive protein was determined using a Tina-quant® C-reactive protein (latex) 
high sensitive assay (Roche Diagnostics, Indianapolis, IN). The serum sample was 
mixed with a buffer (Tris(hydroxymethyl)-aminomethane 16 mmol/L, pH 7.4) this 
was then added to the reagent (latex particles coated with anti-CRP mouse 
monoclonal antibodies). The reagent then reacts with antigen in the sample to form 
an antigen/antibody complex which is then measured turbidimetrically using a 
Roche/Hitachi 902 analyser (Roche Diagnostics, Indianapolis, IN).
The measuring range for the assay is 0.1-20 mg/L, For those C-reactive protein 
values above 20 mg/L the serum was diluted with 0.9% NaCl to give a value within 
the measuring range and the result multiplied by the dilution factor(190).
Those patients with a C-reactive protein greater than lOmg/L were considered to 
have a clinically significant inflammatory response.
Interleukin-6
11-6 was measured using a quantitative sandwich enzyme immunoassay technique. 
The Quantikine® HS immunoassay kit (R+D Systems Europe, Abingdon) was used 
for measurement. This contained E. co//-expressed recombinant human IL-6, which 
is essentially added to each sample and forms an antibody-antigen complex with IL-6 
present in each sample. A polyclonal antibody specific for IL-6 is then added. The 
reaction is then amplified and a colour develops in each microplate. The 
development of the colour is stopped then the optical density is measured to 
determine the concentration of IL-6 in each sample.
The steps in the analysis are summarised in figure 15. Firstly lOOpl of sample is 
added to each well of a microplate. Each well is pre-coated with mouse monoclonal
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antibody against IL-6. lOOuL of assay diluent (a buffered protein base with 
preservatives) is then added to each plate. The microplate is then incubated for 2 
hours at room temperature on a horizontal orbital microplate shaker. The wells were 
then washed with a wash buffer 6 times. 200 pL of 11-6 conjugate (the polyclonal 
antibody against IL-6) was then added to each well and the microplate incubated for 
2 hours on the microplate shaker. The microplate was then washed six further times 
with the wash buffer. 50pL of substrate solution were then added to each well and 
the plate incubated for a further 60 minutes at room temperature. 50 pL of amplifier 
solution were then added to each well and the solution left to incubate for a further 
30 minutes. Following addition of the amplifier colour began to develop then 50 pL 
of a stop solution was added to each well.
The microplates were then read (within 30 minutes) using a Multiska Ascent Plate 
Reader and associated software (Thermo Life Sciences, Basingstoke). The reader 
was set to 490nm optical density and the optical density of each sample was 
measured. The concentration of IL-6 was determined by first finding the absorbance 
value on the y-axis, extending a line to the standard curve and determining the x 
coordinate of the point of transaction (see figure 16), this gives the concentration of 
11-6 in pg/mL.
Those patients with an 11-6 concentration than 5pg/mL were considered to have a 
clinically significant inflammatory response.
Scoring
A “CRP score” and an “11-6 score” were calculated for each subject. A score of one 
was given for a CRP greater than 10 either pre or post operatively. A score of one n 
was also given for an IL-6 concentration over 5pg/mL either pre or post operatively. 
This meant that each subject scored 0,1 or 2 for their CRP score and their 11-6 score 
(table 17)
Statistical Analysis
All data was entered onto SPSS for Windows version 9 (SPSS, Chicago, IL) for 
statistical analysis. Mean CRP concentration was compared for various groups of
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patients to assess if CRP was related to demographic, treatment or pathological 
factors using a t test or ANOVA (where more than two groups were being 
compared). The relationship between clinicopathological factors as well as pre and 
post operative CRP and IL-6 and survival was detennined using cox regression 
analysis for both the univariate and multivariate analysis. In addition, log rank 
testing was used to give a crude estimate of the relationship of CRP score with 
suiwival a Kaplan Meier curve was plotted. CRP score was then subjected to Cox 
regression analysis as well P values less than 0.05 were considered statistically 
significant.
Ethical Approval
Ethical approval for the study was obtained from the local research ethics committee.
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ASSAY PROCEDURE SUMMARY
1. Prepare all reagents and standards 
as instructed.n
2. Add 100 fiL Assay Diluent RDI-75 to each well. Assay 
Diluent RDI-75 may contain a precipitate.
Mix well before and during use.n
3- Add 100 pL Standard or sample to each well. 
Incubate 2 hrs. at RT on the shaker.57
4. Wash 6 times.57
5. Add 200 pL Conjugate to each well.
Incubate 2 hrs. at RT on the shaker.57
6 -  Wash 6 times.57
7. Add 50 pL Substrate Solution to each well. 
Incubate 60 min. at RT on the benchtop.57
8. Add 50 pL Amplifier Solution to each well. 
Incubate 30 min. RT on the benchtop.57
9. Add 50 pL Stop Solution to each well.
Read at 490 nm within 30 min.
X correction 650 or 690 nm
Fig 15 : Summary of procedure for IL-6 measurement (191)
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C alib rato r D iluent R D 6-11
10
1
0.1
0.01
0.1 1 10
hum an  IL-8 C o n o an tra tlo n  (pg/m L)
pg/mL
0
0.156
0.312
0.625
1.25
2.5
5
10
O.D.
0.130
0.134
0.166
0.173
0.218
0.223
0.296
0.311
0.447
0.469
0.7310.773
1.348
1.401
2.389
2.566
Average
0.132
0.170
0.221
0.304
0.458
0.752
1.375
2.478
Fig 16: Calibration curve for calibrator diluent to illustrate how to measure IL -6  
concentration
Corrected
0.038
0.089
0.172
0.326
0.620
1.243
2.346
Table 17: Calculation o f  CRP and 11-6 score. Possible scores 0,1 i
Pre-operative Score Post-operative Score
CRP <10mg/l 0 CRP<10m g/l 0
CRP >10mg/l 1 CRP > 1 Omg/1 1
11-6 <5ng/l 0 11-6 <5ng/l 0
11-6 >5ng/l 1 11-6 >5ng/l 1
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Results
In total 194 patients were recruited for the study. 11 were excluded as they were 
found to have métastasés at presentation; had palliative resection or were found to 
have a second non-breast primary at diagnosis. 183 patients were therefore included 
in the study, 81 patients from hospital 1 and 102 from hospital 2. 154 patients had a 
second blood sample taken post operatively at approximately 12 months. 4 of the 
remaining patients had died in the intervening period and the remainder did not have 
a blood sample taken (25 patients).
The demographics of the patients are shown in table 18. The majority of patients 
were over 50 (86.9%), non smokers (67.8%) and of intermediate deprivation 
category (48.6%).
Table 18: Demographic characteristics of the patients
Number of Patients Percentage of patients
Age
<50 24 13.1
>50 159 86.9
Smoker 49 27.7
Non-smoker 124 67.8
Unknown 10 5.5
Deprivation category
Affluent 21 11.5
Intermediate 89 48.6
Deprived 73 39.9
Hospital of Treatment
1 81 44.3
2 102 55.7
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The pathological data for the patients is as shown in table 19. The majority of 
patients had intermediate prognosis tumours (49%) that were ER positive (80%) and 
HER2 negative (77%). The adjuvant treatment the patients received is shown in 
table 20. of the study population, 39% had chemotherapy, 64% had radiotherapy and 
81% had tamoxifen
Table 19: Pathological characteristics of the patients
Patients(%) n=183
Tumour size
<2cm 114(63)
>2cm 69 (37)
Grade
I 40 (22)
II 60 (33)
III 83 (45)
Involved lymph node
0 104 (57)
1-3 49 (27)
>3 30(16)
NPI
Good (<3.4) 61 (33)
Intermediate (3.41- 5.4) 89 (49)
Poor (>5.4) 33(18)
Oestrogen receptor status
Negative 37 (20)
Positive 146 (80)
HER2 status
Positive 18(10)
Negative 141 (77)
Unknown 24
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Table 20: Adjuvant treatment received by the study population
Adjuvant treatment Number of patients (%)
Chemotherapy
Yes 72 (39)
No 92 (50)
Unknown 19(11)
Radiotherapy
Yes 117(64)
No 48 (26)
Unknown 18(10)
Hormonal therapy
Yes 148 (81)
No 35(19)
At follow up on 31®^ July, 2005, 19 patients had died of breast cancer and 11 of 
intercurrent disease. A further 6 patients had had local recurrence which had been 
successfully treated by resection. The median follow up was 53 months (range 42.4 
to 57.8 months).
On measuring pre-operative serum CRP the minority of patients (11%) had a 
clinically significant inflammatory response (CRP>10 mg/L). The same was true for 
11-6. 11% of patients had a clinically significant 11-6. Similar findings were tme of 
the post-operative CRP, 12% of patients had a clinically significant inflammatory 
response. 18% of patients had a clinically significant 11-6 post-operatively (see table 
21).
Natasha C Henley, 2006
Chapter 4
121
Table 21 : Pre op CRP (mg/1) and IL-6 (pg/l) results (n =183) and post op results 
(11=154)
Number of patients
Pre op CRP (n = 183)
<10 mg/1 162 (89)
>10 mg/1 21(11)
median (range) 2.28 (0.10-22.78)
Pre op IL-6 (n = 183)
<5 pg/l 163 (89)
>5 pg/l 20(11)
median (range) 2.08 (0.50-25.08)
Post op CRP (n = 154)
<10 mg/1 134 (88)
>10 mg/1 19(12)
median (range) 2.40 (0 .1-93 .5)
Post-op IL-6 (n = 154)
<5 pg/l 125 (82)
>5 pg/l 28(18)
median (range) 2.4 (0.4-25.8)
On calculating the CRP score, the majority of patients scored 0 (80%), 16% of 
patients scored 1, and 4 % scored 2. The majority of patients had an 11-6 score of 0 
(80%), 14% scored 1 and 5% scored 2 (see table 22).
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Table 22: CRP and IL-6 scores (n=154)
No. patients (%)
CRP Score
0 122 (80)
1 25 (16)
2 6(4)
IL-6 Score
0 122 (80)
1 21 (14)
2 10(6)
On t testing (and ANOVA for more than two comparisons), mean pre or post 
operative CRP was not related to age, deprivation category or smoking status. Pre­
operative CRP had no statistically significant relationship to Nottingham prognostic 
index, ER status or HER 2 status. Post - operative CRP had no relationship to 
whether the patients had postoperative radiotherapy or chemotherapy or the HER2 
status of their tumours. However, mean post-operative CRP was significantly greater 
in patients with a high NPI compared with those with intermediate or low NPI (22.8 
compared with 7.03 and 5.53 respectively; p=0.012). Post-operative CRP was also 
significantly greater in patients with ER negative tumours (p=0.001) (table 23). Pre 
and post operative IL-6 was not related to age, deprivation, smoking, NPI, ER, HER2 
or adjuvant therapy (table 24).
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Table 23: Comparison of serum CRP with clinicopathological characteristics of the 
study group
Variable Mean pre op CRP P Mean post op CRP P
Age
<55 3.22 0.075 5.43 0.87
>55 4.45 5.73
Deprivation^
Affluent 3.34 0.24 3.08 0.32
Intermediate 3.86 6.94
Deprived 4.40 4.79
Smoking
Yes 3.80 0.41 4.84 0.26
No 5.41 6.79
NPIt
Good 3.95 0.75 5.53 0.012*
Intermediate 4.23 7.03
Poor 3.56 22.82
ER status
Positive 3.88 0.41 4.07 0.001*
Negative 4.56 11.35
HER2 status
Positive 2.74 0.22 2.58 0.23
Negative 4.09 6.42
Tamoxifen 0.004*
Yes N/A 4.54
No 9.95
Chemotherapy
Yes N/A 4.57 0.11
No 7.83
Radiotherapy
Yes N/A 5.32 0.73
No 6.07
T test to compare mean CRP between groups. fANOVA to compare mean CRP 
between groups.
* Statistically significant
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Table 24; Comparison of serum IL-6 with clinicopathological characteristics of the 
study group
Variable Mean pre op IL-6 P Mean post op IL-6 PAge
<55 2.49 0.07 3.72 0.22
>55 3.36 4.82
Deprivationf
Affluent 1.84 0.12 3.06 0.11
Intermediate 3.04 4.63
Deprived 3.43 4.61
Smoking
Yes 3.10 0.85 4.21 0.52
No 3.21 4.86
NPIf
Good 2.92 0.14 4.45 0.14
Intermediate 2.79 3.74
Poor 4.01 6.30
ER status
Positive 2.93 0.28 4.39 0.86
Negative 3.55 4.57
HER2 status
Positive 2.30 0.28 4.61 0.21
Negative 3.14 2.84
Tamoxifen 0.703
Yes 4.36
No 4.73
Chemotherapy
Yes 3.60 0.33
No 4.40
Radiotherapy
Yes 4.10 0.71
No 4.45
T test to compare mean IL-6 between groups. fANOVA to compare mean CRP 
between groups.
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On univariate analysis of patients who had had a pre-operative blood sample taken, 
NPI (p<0.001), ER status (p=0.012), HER2 status (p=0.035) and pre operative CRP 
(p=0.044) were significantly related to survival (table 25). However, on 
multivariate analysis only NPI (p<0.001) and pre operative CRP (p=0.03) were 
significantly predictive of survival (table 26)
Table 25: Univariate Cox regression survival analysis of pre operative CRP and IL-6 
only (n= 183)
P HR 95% Cl
Age 0.07 1.03 0.69-2.10
Smoking 0.16 1.78 0 .10-1 .07
Deprivation (affluent/ intermediate/ deprived) 0.52 1.20 0 .79-4 .02
NPI (good/intermed/poor) <0.001* 5.60 3.04-10.31
ER (pos/neg) 0.012* 0.39 0.18-0.81
HER-2 (pos/neg) 0.035* 2.68 1.07-6.72
Serum pre operative CRP 0.044* 1.07 1.00- 1.14
Serum pre operative 11-6 0.079 1.07 0.99-1.15
Table 26: Multivariate Cox regression survival analysis of pre-operative CRP and IL- 
6 (n=183)
P HR 95% Cl
NPI
(good/intermed/poor)
<0.001* 5.69 2.68-12 .09
ER
(pos/neg)
0.21 0.59 0 .26-1 .34
HER-2
(pos/neg)
0.72 1.19 0.46-3.11
Serum pre operative CRP (CRP<10/ CRP >10) 0.03* 3.78 1.18-12.15
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On univariate analysis of patients who had had both a pre and post-operative blood 
sample taken again NPI (p<0.001), ER (p=0.0I2), HER2 (p=0.035) and preoperative 
CRP (p=0.044) predicted survival, however so did post-operative IL-6 (p=0.04)(table 
27). On multivariate analysis of these patients, only NPI (p<0.001) and pre-operative 
CRP (p=0.04) predicted survival (table 28).
Table 27: Univariate Cox regression survival analysis including post operative CRP 
and IL-6 (n 153)
P HR 95% Cl
NPI (good/intermed/poor) <0.001* 5.60 3.04-10.31
ER (pos/neg) 0.012* 0.39 0.18-0.81
HER-2 (pos/neg) 0.035* 2.68 1.07-6.72
Serum pre operative CRP 0.044* 1.07 1.00- 1.14
Serum pre operative 11-6 0.079 1.07 0.99-1.15
Serum post operative CRP 0.22 1.97 0 .6 7 -5 .8
Serum post operative 11-6 0.04* 2.86 1.06-7.71
Table 28: Multivariate Cox regression suiwival analysis including post operative 
results
P HR 95% Cl
NPI (good/intermed/poor) <0.001* 5.41 2.34-12.51
ER (pos/neg) 0.53 0.74 0.29-1.89
HER-2 (pos/neg) 0.95 1.04 0 .32-3 .39
Serum pre operative CRP
(CRP<10/ CRP >10)
0.04* 4.13 1.10-15.50
Serum post operative 11-6
(IL-6<5/ IL-6>5)
0.38 1.70 0 .52-5 .55
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When CRP and IL-6 were expressed as a score to examine the longitudinal 
relationship, log rank testing showed that CRP score predicted survival (p = 0.003 
table 29/ fig 17) but IL-6 score did not (p=0.171 -  table 30/ fig 18).
Table 29: Cumulative survival vs CRP score
1 year 2 year 3 year 4 year
CRP score = 0 1.0 0.975 0.934 0.902
CRP score = 1 1.0 0.880 0.840 0.800
CRP score =2 1.0 0.833 0.667 0.500
Log rank p=0.003
1.0
CRP score
CRP score
> 6I 5
W .4
(1)> .3
I  2
i  -1-Ü 0.0
10 20 30 40 50 60
SirvivQl (rronths)
Fig 17: Kaplan Meier plot of CRP score vs survival
Natasha C Henley, 2006
Chapter 4
128
Table 30: Cumulative survival with 11-6 score
I year 2 year 3 year 4 year
IL-6 score = 0 I.O 0.975 0.934 0.893
IL-6 score = I I.O 0.905 0.810 0.810
IL-6 score =2 1.0 0.900 0.800 0.700
Log rank = 0.171
1.0
.9 11.-6 score =  0
11 .-6 score =
CD> 6
3 -5-(I) .40)
è  -3-
I  .2
1  1Ü 0.0
10 20 30 40 50 60
SLTv^ val (rronths)
Fig 19: Kaplan Meier plot of survival and IL-6 score. Log rank 0.171
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On Cox regression univariate analysis, survival was predicted by NPI (p<0.001), ER 
status (p=0.018) and CRP score (p=0.004) (table 31). While on multivariate 
analysis, only NPI (p<0.001) and CRP score (p=0.001) score predicted survival 
(table 32).
Table 31 : Univariate Cox regression survival analysis of CRP score and survival
P HR 95% Cl
NPI (good/intermed/poor) <0.001* 4.97 2.52- 9.83
ER (pos/neg) 0.018* 0.37 0.16-0.87
HER-2 (pos/neg)
CRP Score 0.004* 2.36 1.28-4.33
IL-6 Score 0.06 1.71 0.96-3.05
Table 32; Multivariate Cox regression survival analysis of CRP score and survival
P HR 95% Cl
NPI (good/intermed/poor) <0.001* 5.45 2.72-10.8
ER(pos/neg) 0.68 0.82 0.31-2.12
CRP Score 0.001* 2.69 1.47-4.91
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Discussion
These results show that deprivation did not affect the magnitude of the systemic 
inflammatory response. Similar to the results in chapter 1, this data did not 
demonstrate a difference in breast cancer survival between deprived and affluent 
women. What has been shown, however, is that the pre-operative systemic 
inflammatory response (as measured by C-reactive protein but not by IL-6) did 
predict survival from breast cancer in this group of patients, independent of the 
established prognostic pathological factors: Nottingham prognostic index, oestrogen 
receptor or HER2 receptor status. The post-operative systemic inflammatory 
response did not appear to predict survival from breast cancer in these patients. A 
combination of the pre and post operative C-reactive protein to produce a C-reactive 
protein score was a significant predictor of survival in these patients, independent of 
their pathological or demographic characteristics.
The nature of the relationship between deprivation and the systemic inflammatory 
response is not clear. A difference in the background level of inflammation between 
affluent and deprived populations in an apparently “healthy” population has been 
shown in large epidemiological studies (94;95). After correction for smoking and 
obesity, both of these studies still demonstrated a raised CRP in deprived patients. It 
was therefore concluded that because CRP is associated with increased risk of 
cardiovascular events(l 19) that the presence of low grade inflammation in deprived 
groups explained their increase risk. In both of these large studies the difference was 
in the reference range for the nonual population and below the level at which an 
inflammatory response would be considered significant (94;95). This suggests that 
any difference in the magnitude of the systemie inflammatory response between 
socio-economic groups is small. It is not therefore surprising that in this study with 
relatively small numbers that this study was unable to demonstrate a difference in 
CRP concentration between socio-economic groups independent of pathological 
factors. In agreement with the findings of chapter 1 but not, several large 
epidemiological studies(8;10;19;45;48;90), there was no significant difference in 
pathology or survival between socio-economic groups. Therefore, with the small 
numbers involved in this study it has been impossible to demonstiute that a
Natasha C Henley, 2006 131
Chapter 4
difference in systemic inflammatory response might account for survival differences 
between socio-economic groups. Clearly a larger study would be required for this.
A further confounding factor is the magnitude of the systemic inflammatory 
response. The majority of patients in this study did not have a clinically significant 
inflammatory response which further confounded the ability for the study to 
demonstrate any significant differences between socio-economic groups. In 
colorectal cancer a difference in the systemic inflammatory response between socio­
economic groups has been suggested as a reason for survival differences (96). 
However, in colorectal cancer there is a more significant inflammatory response and 
its associated mortality is greater than breast cancer. In the study by McMillan et al 
(2003) although there were smaller numbers of patients with a shorter period of 
follow up there were enough events and a sufficient number of patients with an 
inflammatory response to show a difference between socio-economic groups. With 
longer follow up (for example 10 years), and therefore with more mortality, of the 
cuiTent group of patients with breast cancer it may be possible to show a difference 
between socio-economic groups without a further increase in numbers.
Despite this study not demonstrating a difference between socio-economic groups, it 
has shown that survival from breast cancer can be predicted by the pre-operative C- 
reactive protein but not the post operative C-reactive protein, independent of other 
pathological factors. However, combining the two to create a “CRP score” is a 
strong predictor of survival in breast cancer. Interleukin-6 was less successful at 
predicting survival than C-reactive protein.
The ability of the pre-operative systemic inflammatory response to predict survival in 
this group of patients with primary operable breast cancer confirms findings in 
colorectal, bladder, prostate, lung, lymphoma, pancreatic and gastric carcinomas. 
Although it has not been confirmed in primary breast cancer before, a raised 
systemic inflammatory response has been demonstrated in patients with metastatic 
(118) and locally advanced (116) breast cancer.
Contrary to previous studies, this study was unable to demonstrate a relationship 
between IL-6 and breast cancer survival. A raised post-operative IL-6 was
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associated with sm-vival on univariate analysis but the relationship lost its 
significance on multivariate analysis. Raised serum IL-6 has been shown to be 
associated with poor prognosis in patients with metastatic breast cancer and patients 
with locoregional disease (102; 113-115) but has not previously been shown to be 
associated with survival in patients with primary operable breast cancer. In fact the 
relationship between survival, serum IL-6 and other types of cancer is somewhat 
inconsistent. Few studies have shown a raised IL-6 in patients with cancer even in 
those losing weight (101), who would be expected to have the greatest inflammatory 
response. It therefore appears that the majority of IL-6 produced in response to 
cancer is produced locally in the tissues and little of it spills over into the circulation. 
So it is not surprising that in the present study of patients with primary breast cancer 
that not only was 11-6 not raised, it was also unable to predict prognosis.
Post-operative C-reactive protein did not predict survival as was previously shown in 
colorectal cancer (192). However, the number of patients who had a post-operative 
C-reactive protein was smaller than those who had a pre-operative level measured so 
it may have been due to relatively small numbers that this relationship was not 
significant. In addition, the low mortality and relatively short follow up may also 
have contributed. A further study with larger numbers and longer follow up would 
be required.
While the pre-operative systemic inflammatory response but not the post-operative 
one should deteiuiine prognosis may simply be a function of the number of patients 
in the study, there may also be other reasons. The systemic inflammatoiy response is 
a reflection of the host response to the tumour rather than the malignant potential of 
the tumour itself. It is also a reflection of the background “stress response” of the 
patient even without the presence of a tumour, deteiTnined by the presence of pre­
existing cardiovascular disease, obesity and smoking (94;95). The presence of the 
“background response” also appears to reflect cancer incidence but more importantly 
the likelihood of cancer mortality (193). The fact that the pre-operative but not the 
post-operative systemic inflammatory response was important suggests that it is the 
presence of a tumour that is more important in the genesis of this response rather 
than co-morbidity. However, this study did not include age and co-morbidity 
matched controls so no definite conclusion can be drawn on this. An alternative
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explanation is that if the systemic inflammatory response is a reflection of the tumour 
load then a post-operative measurement should be able to detect the presence of 
micrometastases or sub-clinical disease. As this study has shown breast cancer does 
not induce a large systemic inflammatory response so the presence of sub-clinical 
disease or micrometastases would be unlikely to either.
Despite the inability of the post-operative C-reactive protein to predict suiwival, 
when it is combined with the preoperative C-reactive protein and expressed as a 
“CRP score” to examine the longitudinal relationship between C-reactive protein and 
survival, the “CRP score” is a strong predictor of survival. The reasons for this are 
not clear. By examining the longitudinal relationship a measure is obtained of the 
host response to the tumour but also the background “inflamed state” of the subject. 
Chronic inflammation is thought to promote carcinogenesis. A study of background 
level of inflammatory markers (ineluding C - reactive protein) in healthy subjects 
showed that a raised C-reactive protein was associated with an increased risk of 
cancer incidence and also of cancer death (193). The patients with both a pre and 
post-operative systemic inflammatoiy response therefore receive a “double hit.” 
Firstly, they already have a raised background inflammatoiy response but they are 
also mounting a raised systemic inflammatory response to their tumour. This may 
result in worse survival.
The “double hit” might also explain why deprived patients have a worse outcome 
from breast cancer than affluent women. Although it has not been demonstrated with 
this data, deprived patients may have a raised background systemic inflammatory 
response due to increased BMI, smoking and cardiovascular co-morbidity. They 
then develop a cancer and therefore in addition to the systemic inflammatory 
response to the tumour they are also in a more “inflamed state” and this gives rise to 
a poorer prognosis. Due to the small number involved in this study and the small 
number of events this process has not been demonstrated here and a larger study 
would need to be conducted to show this effect.
There are, however, several other possible explanations for why the CRP score 
should be a strong predictor of survival. It may be due to the initial response to the 
tumour being of sufficient magnitude pre-operatively that is maintained after the
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tumour has been removed and all adjuvant therapy has been completed. A further 
explanation is that the presence of an inflammatory response post-operatively is due 
to the continued presence of malignant cells, either in the form of micrometastases or 
sub-clinical disease. Whatever the reason for a continued inflammatory response 
post-operatively, the result is an increase in the host metabolic rate leading to cancer 
associated malnutrition, cachexia and eventually death.
The cellular mechanisms behind the relationship between C-reactive protein and 
breast cancer survival are not clear. Tumour growth and metastasis is a complex 
process which involves mechanisms at the site of the tumour and distant to the 
tumour. The cytokines, including IL-6, released by the tumour itself as well as the 
sunounding tissues cause local tissue damage and tumour necrosis. These also spill 
over into the circulation to act on the liver to produce the acute phase reactants, one 
of which is C-reactive protein. While some of these effects are beneficial in 
initiating a host immune response to the tumour and limiting tumour growth, they 
can also be detrimental because an enhanced inflammatory response can actually 
promote tumour growth and metastasis.
In breast cancer, the presence of a large lymphocytic infiltrate into the tumour 
increases the likelihood of local recunence( 194) and confers a poor prognosis. This 
suggests that the resulting systemic inflammatory response is due to production by 
the tissues at the site of injury rather than the tumour itself. A similar situation exists 
in renal cancer, where the presence of a large lymphocytic response results in a poor 
prognosis (111). This eontrasts with colorectal (110) and gastro-oesophageal cancer 
(195) where a poor lymphocytic infiltrate is associated with a poor prognosis and a 
raised C-reactive protein, hi gasti'ointestinal tumours the tumour itself must 
therefore be the source of the interleukins which induce then systemic inflammatory 
response. Indeed in the study by Ganna et al (2005), a poor lymphocytic infiltrate 
was associated with a raised C-reactive protein.
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Conclusions
This study has shown that, in this group of breast cancer patients, there is no 
association between socio-economic deprivation and the magnitude of the systemic 
inflammatory response. There was no difference in survival between deprivation 
categories. This study has, however, shown that the presence of a systemic 
inflammatory response predicts survival from breast cancer independent of known 
and established predictors of outcome. The presence of a systemic inflammatory 
response pre-operatively is more prognostic and a post-operative response.
However, combining the pre and post operative response and expressing then as a 
score is a strong predictor of outcome.
Clearly the pathological factors are most important in determining outcome ad 
prognosis in patients with primaiy operable breast cancer. In addition, the oestrogen 
receptor and the HER2 receptor status are important in determining adjuvant therapy. 
However, the systemic inflammatory response could prove to be a useful adjunct to 
these established prognostic factors. While there is no suggestion that patients with a 
systemic inflammatory response should be excluded from having surgery, they might 
benefit from manipulation of the inflammatory response pre and/or post operatively 
with non-steroidal anti-inflammatory drug or the newer COX 2 inhibitors. If it could 
be shown in a larger study with longer follow up, that patients from more deprived 
socio-economic backgrounds did indeed have a larger systemic inflammatory 
response, then adjuvant treatment of this group of patients, who have a worse 
outcome from breast cancer, might help to redress the balance.
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Chapter 5 
Conclusions
The assumption prior to commencing this piece of work was that the greater 
Glasgow Audit database would confirm the findings in previous work that there 
exists a deprivation gap in outcome for women with primary breast cancer. 
Surprisingly this has not been shown. However, the studies on which this 
assumption was based are to some extent historical and are based on populations 
diagnosed prior to the establishment of breast screening and MDT working. The 
data presented here are for women diagnosed in the post-breast screening era who 
have been treated in the context of a multidisciplinary team. The fact that no 
deprivation gap has been demonstrated suggests that the introduction of these two 
changes may have helped to eliminate the effect of socio-economic factors on 
outcome.
What really highlights this effect is that although deprived women have worse 
pathology in terms of tumour size and nodal status, even on the univariate analysis 
without correcting for these factors, they still do not fare any worse than more 
affluent women. Treatment for breast cancer has evolved in recent times with the 
introduction of the specialist breast surgeon, less extensive surgery, the introduction 
of anthracycline based chemotherapy, the aromatase inhibitors and most recently 
herceptin. While all of these factors have no doubt contributed to improved outcome 
across the board, the way in which breast cancer services are delivered has also 
played a large part.
Breast cancer treatment used to vary widely between geographic regions, Health 
Authorities (in England) and Health Boards (in Scotland) had no doubt contributed to 
socio-economic disparities. However, the introduction of the multidisciplinary team 
has ensured that the developments in breast cancer are introduced more uniformly for 
all patients with specialists working across different regions. Therefore, all women 
benefit from better and optimal treatment of their breast cancer.
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However, the findings of chapter 2 suggest that even being treated by a specialist 
breast surgeon does not necessarily mean that everyone is treated equally. The 
mastectomy rate in Glasgow is slightly above average for the UK as a whole, with 
deprived women being more likely to have a mastectomy than more affluent women. 
From the data, this appears to be a reflection of larger tumour size in deprived 
women and would suggest that this is entirely appropriate. The wide variation in 
mastectomy rate between hospitals is, however, cause for concern. Although broadly 
speaking women are being treated appropriately, variations between surgeons 
suggest that there is still a lack of consensus on the best treatment. Despite the 
extensive evidence of the efficacy of conservation surgery there still appears to be a 
reluctance to accept it as equivalent to mastectomy. The variation between hospitals 
may be due to patient choice but most of the populations served by the individual 
hospitals are relatively heterogeneous so it is more likely that variation is due to the 
surgeons’ preferences. Mastectomy is now thought to be associated with excessive 
psychological co-morbidity so it is a matter of urgency that this is recognised and 
attempts are made to utilise conservation surgeiy in women in whom it is 
appropriate.
A further issue that has been highlighted from this analysis of the Greater Glasgow 
Audit Database is the poor attendance at screening for women from deprived socio­
economic groups. This is a well recognised phenomenon, however, breast screening 
has been available since 1991 and it would be hoped that these socio-economic 
differences in uptake would have been ironed out. Women from deprived areas seem 
to be as likely to attend their GPs with breast cancer related problems and appear to 
have little in the way of delay in presentation however breast screening still appears 
to be in some way less acceptable. Further efforts need to be made to address this 
and raise public awareness of breast screening.
The rising incidence of breast cancer but falling mortality may be due to changes in 
treatment and delivery of healthcare, they may also be due to a change in the 
hormone sensitivity of breast cancer. Comparison of the data on ER status from the 
Greater Glasgow Audit database with a group of patients diagnosed in 10 years 
previously has shown that there has been an increase in the proportion of ER positive 
breast cancer. While there are significant methodological differences in the
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estimation of ER status between the two cohorts of patients, these differences cannot 
be explained by methodology alone. Over a similar time period there have been 
changes in the hormone related aetiological factors behind ER positive breast cancer. 
HRT use has increased; more women are nulliparous and have a later age at first 
pregnancy.
Non-hormonal factors which might have an influence are the rise in obesity and the 
introduction of breast screening which tends to identify ER positive breast cancers. 
Although the incidence of these factors has increased for all women they have 
increased more in affluent women and might explain why affluent women have 
better outcome. The data presented here did not confirm that there has been a greater 
increase in affluent women than deprived women. This may be a function of 
inadequate sample sizes as combining the early and late cohorts of patients 
demonstrated a difference in ER status between different deprivation categories.
Although there may be differences in pathology or aetiology between socio­
economic groups the underlying reason for differences in outcome may relate to the 
host response to the tumour. The data presented in chapter 4 demonstrated that the 
pre-operative systemic inflammatory response to breast cancer predicted survival. 
The post-operative systemic inflammatory response did not predict survival. The 
post-operative systemic inflammatory response is a surrogate for the background 
“inflamed state” of the patient. Combining the pre and post operative systemic 
inflammatory response as a score gave a significant predictor if survival independent 
of tumour pathology or demographic factors.
Deprived patients are known to have a raised “background” systemic inflammatory 
response compared to more affluent women due to a higher incidence of obesity, 
smoking and cardiovascular disease. Although there was no demonstrable 
difference in CRP scores between the deprivation categories (probably due to small 
numbers), the systemic inflammatory response could potentially be reason why 
deprived patients appear to have worse outcome from breast cancer. They already 
have a background raised inflammatory state, due to cardiovascular disease, smoking 
and obesity. They then develop a cancer which triggers an additional systemic
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inflammatory response and it is the combination of the two rather than simply the 
response to the cancer alone that results in a poor outcome.
Although there are disparities between affluent and deprived women in tenus of the 
breast tumours they develop and the treatment they receive, it does appear that 
despite this there no longer exists a significant deprivation gap between rich and 
poor. Whether this finding will be borne out with longer follow up is not clear, 
however, it does appear that improvements in the way that healthcare is delivered has 
had the greatest effect.
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Abbreviations
ANOVA Analysis of variance
ATAC Arimidex, tamoxifen alone or in combination
BMI Body mass index
C/EBPP CAAT/ enhancer-binding protein
Cl Confidence interval
CMF Cyclophosphamide, methotrexate and fluorouracail
COX 2 Cyclo-oxygenase 2
CRP C-reactive protein
DCIS Ductal carcinoma-in-situ
Dep Cat Deprivation category
EDTA Ethylenediamine tetraacetic acid
EQA External quality assessment
ER Oestrogen receptor
FISH Fluoroscopic in situ hybridisation
GGFIB Greater Glasgow Health Board
HER-2 Human epidennal growth factor receptor 2
HR Hazard ratio
HRT Hormone replacement therapy
lARC International Agency for Research on Cancer
IFN Interferon
IHC Immunohistochemistry
IE Interleukin
ISD Information statistics division
JAK Janus protein tyrosine kinase
LBA Ligand binding assay
MCN Managed clinical network
MDT Multi-disciplinary team
NHSBSP National Health Service Breast Screening Programme
NPI Nottingham prognostic index
OR Odds ratio
PR Progesterone receptor
RNA Ribonucleic acid
SEER Surveillance epidemiology and end results
SPSS Statistical package for the social sciences
STATS Signal transducer and activator of transcription 3
TGF Transfoiining growth factor
TNF Tumour necrosis factor
TNM Tumour nodes metastasis
UICC International Union Against Cancer
UK United Kingdom
USA United States of America
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